I am a moderate to aggressive investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
July 6th 2017
Maxtech Signs Strategic Agreement with Maringá Ferro-Liga S.A of Brazil
Vancouver, British Columbia – July 6th 2017 – Maxtech Ventures Inc. (CSE: MVT) (Frankfurt: M1N) (OTC: MTEHF), (“Maxtech” or the “Company”) is pleased to announce that it has signed a strategic cooperation agreement with Maringá Ferro-Liga S.A of Brazil.
Maxtech’s goal is to become a diversified mining company with a high-grade manganese footprint. The primary business programhas been the assembly and acquisition of key mineral projects for future exploration. In Brazil, Maxtech has positioned itself with more than 50,000 hectares of potential high grade Mn mineralization claims, as previously disclosed in its release of May 4th 2017.
The Company’s long term strategy is to grow organically by building a vertical mining operation to sell high-grade manganese to global markets focused on renewable energy, steel production and fertilizers with Mn additives to increase plant/crop fertility.
Maxtech has entered into an agreement with Maringá Ferro-Liga to enable the joint evaluation, exploration and potential acquisition of project specific manganese assets in Brazil, and if justified, to engage in the development and mining of specific claims. Maxtech and Maringa will sign project-specific agreements between the parties prior to engaging in any operations on properties.The agreement shall have a term of 3 years and is non-exclusive.
Peter Wilson, CEO Maxtech said, “Maringá is a diversified industry leader in the uses of manganese in Brazil, making it the perfect partner for Maxtech. Under this association Maxtech hopes to develop more than an exploration partner, enabling the Company to explore, mine and distribute manganese in Brazil with an industry leader.”
Luis Pessoa, Commercial Director from Maringá Ferro-Liga said, “Having a reliable and local source of high grade manganese ore is an important competitive advantage to Maringá. The cooperation agreement with Maxtech enables us to profit from their well recognized know-how to research and explore potential areas in Brazil.”
About Grupo Maringá
Founded in 1946, Grupo Maringá now has over 2,000 employees with over USD $200 million in 2016 revenues. The Maringá companies are located in the states of Paraná and São Paulo. They produce sugar cane, sugar, ethanol, energy and manganese alloy. Maringá Ferro-Liga S.A. is a subsidiary of Grupo Maringá and is located in Itapeva, State of São Paulo. It is the second largest manganese ferroalloy producer in South America, producing high quality silico-manganese and high-carbon ferromanganese.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
Phone: 604-484-8989
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information
Maxtech Ventures Inc. to Attend the IMnI International Manganese Institute Annual Conference
VANCOUVER, BC--(Marketwired - June 02, 2017) - Maxtech Ventures Inc. (CSE: MVT)(CSE: MVT.CN)(CNSX: MVT)(FRANKFURT: M1N)(OTC PINK: MTEHF), ("Maxtech" or the "Company")
Is pleased to announce that the Company will attend the global International Manganese Institute ("IMnI") Annual Conference in Miami, Florida, USA on June 5th to June 7th.
Maxtech will join more than 120 delegates at the IMnl conference in Miami. The Company will be one of very few Canadian representatives. Glencore International AG, Ferroglobe, Maringa Ferro Ligas, United Manganese of Kalahari, are just a few companies being showcased at the conference which will be attended by global manganese leaders traveling from South Africa, Japan, Singapore, Germany, Brazil to highlight just a few of the participating countries. It is a conference not only focused on networking amongst industry peers, but informative break out educational sessions led by the institute directors and professionals in the field to discuss the manganese industry evolution and its increasingly fast pace growth trajectory and affect on many industries and the worldwide green energy revolution.
Peter Wilson, CEO of Maxtech, states, "As Maxtech continues to broaden its direct interests in the manganese industry globally, it is imperative we know who all the players are. The IMnI is a 42 year old association of the industry itself and there is no better way to get involved than to attend their annual event and meet companies that are both upstream and downstream from Maxtech in the manganese supply chain. Maxtech is an exploration company acquiring only the highest grade managense assets with a goal of becoming one of the largest Mn stakeholders in the world."
About International Manganese Institute
The International Manganese Institute (IMnI) is a not-for-profit industry association that represents manganese ore and alloy producers, manufacturers of metallurgical products or chemical compounds, trading houses, industry service providers, companies involved in Mn business development, universities and research organizations around the world. Founded in 1975, with headquarters in Paris, France, IMnI's mission is to provide vision and guidance to the Mn industry by promoting economic, social and environmental responsibility and sustainability to all stakeholders.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
For additional information see the Company's web site at http://www.maxtech-ventures.com
Further information about the Company is available on www.SEDAR.com under the Company's profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
MaxTech Ventures Inc.
Email: info@maxtech-ventures.com
Phone: 604-484-8989
3D Signatures has $2.55M cash at end of fiscal Q3
3D Signatures Inc (C:DXD) (OTCBB:TDSGF
Shares Issued 46,445,199
Wednesday May 31 2017 - News Release
Mr. Jason Flowerday reports
3D SIGNATURES INC. REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS
3D Signatures Inc. has released its operational and financial results for its fiscal third quarter ended March 31, 2017.
Third quarter highlights:
On January 4, 2017, 3DS announced that its common shares had started trading on the OTCQB Venture Market ("OTCQB") and on the Frankfurt Stock Exchange under the symbols "TDSGF" and "3D0", respectively. The Company also announced that it had secured Depository Trust Company eligibility for its common shares listed on the OTCQB.
On January 6, 2017, the Company announced the appointment of accomplished healthcare industry veteran, Joost van der Mark, as its Chief Business Officer. On January 6, 2017, 3DS announced the closing of the third and final tranche of a fully subscribed brokered private placement. The Company issued a total of 597,082 units pursuant to the third tranche of the private placement, which were sold at $0.75 per unit for gross proceeds to 3DS of $148,800, pursuant to the exercise of the Agent's over-allotment option.
On January 9, 2017, the Company announced that new data from a study published in Urologic Oncology suggested that the use of its proprietary TeloView{A } technology platform may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.
On January 18, 2017, the Company announced that it had awarded 253,125 incentive stock options (the "Options") to its CEO, Jason Flowerday, at an exercise price of $0.79 per share. The Options are exercisable for a ten-year period from the date of grant (January 17, 2017) and will vest in four tranches of 63,281 each, every six months from October 1, 2017 to April 1, 2019.
On February 15, 2017, 3DS announced the appointment of medical diagnostics expert, Harry Glorikian, to its Business Advisory Board ("BAB").
On February 21, 2017, 3DS announced a presentation at the 24th International Molecular Medicine Tri-Conference in San Francisco, CA, by its co-founder and principle inventor, Dr. Sabine Mai, on the results of a prospective blood-based prostate cancer pilot study using its TeloView{A } software platform. Based on blinded blood samples, TeloView{A } correctly predicted the stability and aggressiveness of disease for each of the study's 50 intermediate risk prostate cancer patients.
On February 23, 2017, the Company announced the initiation of the validation program for its Hodgkin's lymphoma test, "Telo-HL".
On March 14, 2017, 3DS announced that it had made the final payment to CancerCare Manitoba ("CCBM") for the purchase of intellectual property, all of which had been assigned from CCMB to 3DS on June 26, 2014.
On March 21, 2017, the Company announced clinical study results which confirm that, based on a swab from the inside of a patient's cheek, its proprietary TeloView{A } software platform has the ability to identify patients with Alzheimer's disease and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer's Disease.
On March 29, 2017, 3DS announced that it had successfully completed internal analytical assay validation for its Telo-HL test pursuant to FDA guidelines. This process is referred to as Stage 2 of the validation program as set out in the Company's news releases dated February 23, 2017.
"The fiscal third quarter was another period of meaningful progress for 3DS, and builds on our accomplishments to both increase awareness of 3D telomere analysis as a disruptive technology and to advance the TeloView{A } platform toward commercialization," said Jason Flowerday, CEO.
Summary Third Quarter Results
For the three months ended March 31, 2017, the Company reported a net loss of $2,171,822, or $0.04 loss per common share, as compared to a net loss of $570,449 or $0.02 loss per common share for the three months ended March 31, 2016. The increase in net loss is primarily due to increases in salaries, wages, benefits and stock-based compensation as a result of the Company's hiring of additional employees, as well as the appointment of a new BAB member, to support its global growth strategy. Additional increases in professional fees and investor relations costs are the result of 3DS becoming a publicly traded company in September 2016.
As at March 31, 2017, the Company's cash amounted to $2,552,822.
The Company's financial statements and management's discussion and analysis are available on www.sedar.com.
About 3DS 3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com.
We seek Safe Harbor.
Danny Deadlock Recommendation
4) 3D Signatures (DXD.TSXV 46 cents)
http://www.3dsignatures.com/
I have been monitoring this unique genomics company since March (80 cents). This past week a heavy-handed seller started dumping paper in the 0.40's and it has crushed them. I have no idea why, but this isn't uncommon in May. If there is nothing wrong from a company perspective (which I doubt there is), this could be a great bottom fishing opportunity in the mid 0.40's while this seller exists.
Read through their website for more information, but the potential here may be significant. I like "unique" companies and this is definitely unique in the genomics space.
http://www.3dsignatures.com/science/#page-section-11
http://www.3dsignatures.com/corporate/
3D Signatures is a novel personalized medicine company with proprietary software that can analyze a patient's chromosomal arrangement - or signature - through a simple non-invasive blood test or tissue sample, measuring disease stage and genomic stability, as well as drug efficacy and potential side effects.
Unlike most diagnostic companies, our proprietary imaging software goes beyond identifying whether a patient suffers from a specific disease or condition. Our analytics platform tells doctors how to personalize treatment and best manage the disease for each individual patient.
Maxtech Expands Phase 2 Exploration Due to High-Grade Manganese Assay Results
2017-05-18 00:15 PT - News Release
Maxtech Expands Phase 2 Exploration Due to High-Grade Manganese Assay Results
VANCOUVER, BC--(Marketwired - May 18, 2017) - Maxtech Ventures Inc. (CSE: MVT)(CSE: MVT.CN)(CNSX: MVT)(FRANKFURT: M1N)(OTC PINK: MTEHF), ("Maxtech" or the "Company") is pleased to report that it is expanding exploration activities on Juina claims in Mato Grosso, Brazil.
Maxtech's auger drilling program is being rapidly expanded and carried out on the pre-selected zone at the DNPM 866 271/2017, focusing on sub surface occurrences of manganese bearing cobble horizons up to 60 cm in thickness. Details of the high-grade manganese analyses were announced by the Company in a news release on April 28th. , showing assay values of 52.9% Mn, 55.9% and 51.5% Mn. Additional follow-up with drilling and prospecting near positive holes from Phase 1 exploration will continue. Basic topographic surveys of areas with positive results, combined with a series of lateral holes to address continuity and tonnage will be part of this next phase of work on the ground in Juina.
Due to the positive results the Company will be adding to the team in Brazil immediately. Mapping and delineation of the mineralised zones in addition to the ongoing prospecting is key to future exploration activities on the Juina claims and other acquisitions in Brazil.
Peter Wilson, CEO of Maxtech said, "In order to capitalize on the recent exploration success on our Juina claims it is imperative we expand the scope of our operations. Our Brazilian team is already finding new areas with exactly the same type of mineralisation we encountered previously. We anticipate phase 2 results in the coming weeks."
The technical information contained in this news release has been reviewed and approved by Mr. John Harper B.Sc., P.Geol, who is a Qualified Person with respect to Maxtech's manganese projects as defined under National Instrument 43-101.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
For additional information see the Company's web site at http://www.maxtech-ventures.com
Further information about the Company is available on www.SEDAR.com under the Company's profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, and financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Peter Wilson
Email: info@maxtech-ventures.com
Phone: 604-484-8989
Maxtech forms partnership for Moroccan manganese
Maxtech Ventures Inc (2) (C:MVT)
Shares Issued 48,786,448
Last Close 5/15/2017 $0.44
Tuesday May 16 2017 - News Release
Mr. Peter Wilson reports
MAXTECH FORMS STRATEGIC PARTNERSHIP TO EXPAND MANGANESE EXPLORATION INTO MOROCCO
Maxtech Ventures Inc. has entered into a strategic development partnership with Morocco-based Green Energy Resources (GER) to evaluate established mineral and mining concessions in Morocco for potential acquisition or joint venture.
GER and Maxtech are actively evaluating several advanced stage manganese assets in Morocco with an emphasis on fully permitted mining concessions with established histories of manganese production. These existing permits have been targeted for either 100% purchase or joint venture. The Company expects to report on its negotiations shortly.
The mining industry of Morocco is important to the North Africa region and the national economy of Morocco. The country is the world's third largest producer of phosphate, and contains about 75% of the world's estimated reserves. Mining contributed for approximately 35% of exports and 5% of GDP in 2011. Foreign investors have found the investment climate, infrastructure, fiscal situation, and political stability very favourable to the mining business (http://data.worldbank.org/country/morocco).
Peter Wilson, CEO of Maxtech said "This partnership provides a unique opportunity for Maxtech to expand into Morocco with a goal to eventually supply manganese into the European marketplace. It is an excellent jurisdiction in which to operate and with the help of Green Energy's in-country presence we will be able to evaluate new manganese claims efficiently."
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
THE CAPITAL GAINS CLUB TOP PICK May 12th 2017
OUR TOP BIOTECH PICK: 3D SIGNATURES INC.
(TSXV:DXD and OTCQB: TDSGF)
Predicting the course of diseases and personalizing treatment for the individual patient
“If successful, this could represent a first-in-class blood test which would specifically identify clinically significant prostate cancer. Such a tool does not currently exist for prostate cancer patients” said Dr. Laurence Klotz, the Chairman of the Canadian Urology Research Consortium
Executive Summary: 3D Signatures is a personalized medicine company with a proprietary software platform based on the three-dimensional (3D) analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
Dr. Sabine Mai, is the founder and largest shareholder of the company and is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
Dr. Mai has been instrumental in the development of innovative 3D analysis of genomic instability, which will help in diagnosing more specifically and earlier several forms of cancer. This will allow physicians to personalize treatment and improve the quality of outcomes. During the course of more than twenty years of research she has contributed to a portfolio of patents protecting her discoveries. Her vision is to use her discoveries for the benefit of patients everywhere.
Jonathan Goodman, the CEO of Knight Therapeutics Inc. (over $1 billion market capitalization biotech company) is a key advisor to 3D Signatures. In addition, Knight Therapeutics invested in 3D Signatures and has signed definitive licensing and distribution agreements with the company.
One of the main reasons we like 3D Signatures and the stock is because of its proprietary technology that analyzes a specific part of an individual’s unique DNA (their telomeres) to determine how a disease will progress and if a patient will respond to treatment. This information enables clinicians to measure the appropriateness and effectiveness of different treatments for specific patients.
3D Signature’s technology has over 20 years of research and over $25 million in non-dilutive research & development funding.
No wonder the board and management own approximately 35% of the company!
This is not an early stage biotech company with an undeveloped drug or technology platform – this is a company with an innovative technology and a dedicated team that only makes millions of dollars and saves countless lives if they continue to develop the technology with a view to selling the company to a much larger biotechnology company. We believe the company is poised for exponential gains and we have never sold a share. As the company progresses through various trials and continues to enter into partnerships with other companies, we believe the stock will perform well and the company will attract analysts and large fund managers.
The best way to make large sums of money in a stock is being positioned in a take-over target and that is what we believe 3D Signatures is.
Why a big Pharmaceutical company would acquire 3D Signatures
Hodgkin lymphoma
There are approximately 10,000 new cases of Hodgkin lymphoma and an estimated 1,500 deaths in the United States and Canada each year. Physicians cannot today predict which patients will respond to standard chemotherapy and enter long-term remission or not respond and relapse, requiring alternative but more aggressive forms of therapy. THERE IS CURRENTLY NO TEST TO PREDICT WHETHER PATIENTS WILL RESPOND TO STANDARD CHEMOTHERAPY OR NOT.
Prostate cancer
Every year, there are over three million existing and new cases of prostate cancer in the United States and Canada. A large proportion of these patients are needlessly overtreated and/or subjected to surgery -- costing the health care payers billions of dollars annually and inflicting unnecessary treatment and complications on patients. There is a significant unmet need, at every stage of the disease, for accurate and minimally invasive risk assessment tools to allow clinicians to make better treatment decisions. 3D Signatures wants to arm physicians with the tools necessary to confidently personalize treatment decisions for each individual prostate cancer patient. NO SUCH TESTS CURRENTLY EXIST.
Drug development
Based on published work by Dr. Mai and her collaborators regarding real-time ex vivo feedback on several new therapeutic candidates and inbound interest from a number of major pharmaceutical companies, 3D Signatures is activating a dedicated strategy to engage industry in discussions around partnership opportunities. 3D Signatures' technology has the potential to identify lead therapeutic candidates through drug screening, select specific patients for clinical trials, monitor patients during clinical trials and ultimately work with pharmaceutical companies on the approval of companion diagnostics for precision medicine. There is significant potential value to be realized by pharmaceuticals companies in the form of efficient identification of new drugs, targeted clinical trials, objective real-time feedback during clinical trials and expedited regulatory approval by way of companion diagnostics.
3D Signature’s plan over the course of 2017:
Validation and preliminary approval of its lead prognostic test for Hodgkin lymphoma;
Initiation of a major clinical trial for blood-based monitoring tests for prostate cancer;
Strategic engagement with pharmaceutical companies for development of companion diagnostics; and
Securing the right people and partners to elevate its business.
The Team:
Dr. Sabine Mai: Founder and Major Shareholder
Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba.
Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba.
She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
Jason Flowerday: CEO and Director
over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson.
Jonathan Goodman: Business Advisor
CEO of Knight Therapeutics (investor and partner with 3D Signatures)
The co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later.
The Potential: 3D Signatures is in discussions with multiple pharmaceutical companies, with candidate compounds in all phases of clinical trials, about potentially incorporating 3D Signature’s three-dimensional telomere analysis and proprietary software into their trials. The company can offer these organizations significant insight into the efficacy of their compounds and possibly provide information on dose dependent response, as well as toxicity related to each compound.
On December 7, 2016, 3D Signatures presented the preliminary results of an important collaborative initiative between the company and the Institut Universitaire de Ariologie et de Pneumologie De Quebec (“IUCPQ”) exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (“AC”) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions. In every blinded patient sample the company analyzed, 3D Signature’s technology was able to distinguish between the two respective types of deadly lung cancer. The acquisition of 3D telomere images and analysis was performed in the company's reference lab using the company’s proprietary software platform, TeloView™. A poster was presented at the International Association for the Study of Lung Cancer (“IASLC”) 17th World Conference on Lung Cancer (“WCLC”) which took place in Vienna, Austria from December 4 to December 7, 2016.
3D Signature’s technology has over 20 years of research and over $25 million in non-dilutive research & development funding.
No wonder the board and management own approximately 35% of the company!
The upside potential is huge and there are many catalysts to shoot the stock a lot higher. The company has laid out its business plan and if they continue to execute on time and on budget then we see our exit through a takeover. We hold shares in this company. Will you?
Enjoy the Gains,
Capital Gains Club
C. Sargent, Managing Editor
Copyright © 2017 Capital Gains Club, All rights reserved.
You opted in to receiving emails at www.capitalgainsclub.com Enjoy!
Our mailing address is:
Capital Gains Club
409 Granville
Suite 902
Vancouver, BC V6C1T2
Canada
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
What is a good amount of money to invest in a deal?
For starters, only invest what you can afford to lose. Start small and make some money and then start using your gains as “House Money”. Don’t take big risks with your own money. Make some money then use those profits as you see fit.
Secondly, laws prohibit the Capital Gains Club from giving any personal investment advice. You should consult with your broker or investment advisor about any decisions related to your investments.
Please don’t ever read a stock alert of ours and construe it to mean that we are asking you to buy the stock. We share our analysis on a stock and encourage you to take a look as well. Unlike some other newsletters, we want everyone to succeed otherwise Capital Gains Club won’t survive in the long run.
Disclaimer
The website, its owners, their affiliates, directors, officers, employees, consultants and agents are hereafter collectively referred to as “Capital Gains Club”, “we”, “our” or “us”.
The information and recommendations made available here (“Information”) by Capital Gains Club and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email. We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information. This does not include trusted third parties who assist us in operating our website, conducting our business, or servicing you, so long as those parties agree to keep this information confidential. We may also release your information when we believe release is appropriate to comply with the law, enforce our site policies, or protect ours or others rights, property, or safety. However, non-personally identifiable visitor information may be provided to other parties for marketing, advertising, or other uses.
If you decide to opt-in to our mailing list, you will receive emails that may include company news, updates, related product or service information, etc.
Note: If at any time you would like to unsubscribe from receiving future emails, we include detailed unsubscribe instructions at the bottom of each email.
Please use our site as a place to get ideas and information. Enjoy our news analysis and other information, but never make an investment decision off of anything we say. Do your own research and analysis before buying or selling securities. Only invest an amount you can afford to lose. The Capital Gains Club is not registered as an adviser under the securities legislation of any jurisdiction and provides the Information in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.
In no event will the Capital Gains Club and/or its affiliates, employees, consultants or directors be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. Nothing in this site shall constitute an offer or solicitation to anyone in any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation.
This is not an investment advisory, and should not be used to make investment decisions. Information from the Capital Gains Club is often opinionated and should be considered for information purposes only. The information about companies we profile may contain errors and therefore you should not make any investment decision based on what you read here. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. Read our emails and newsletters as a place to gather ideas and read about our perspective on stocks. Capital Gains Club bases its recommendations and forecasts on techniques, research, analysis and publicly available information believed to be reliable in the past and at the time of publication. However, the Capital Gains Club makes no warranty as to the completeness, accuracy or usefulness of the information presented. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of Capital Gains Club may have positions in the stocks discussed above and may trade in the stocks mentioned. Don’t consider buying or selling any stock without conducting your own due diligence. We do not act in the capacity of any of the following and you should not construe our activities as involving any of the following:
Providing investment advice;
Acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration;
Broker-dealer activities;
Stock picker;
Securities trading expert;
Securities analyst;
Financial planner or financial planning;
Providing stock recommendations;
Providing advice about buy and sell or hold recommendations as to specific securities; or
Offer or sale of securities or solicitation to purchase securities.
You should not interpret any of our publications as investment advice. If you are seeking investment advice you should consult with an registered investment adviser, registered stockbroker, or other financial professional of your choosing.
Whether we receive cash or securities compensation, we fully disclose the receipt or anticipated receipt of such compensation. We may buy and sell securities of the same security we are disseminating information for.
Our activities may involve actual conflicts of interest, since we may receive monetary or securities compensation in the very securities we are providing information on and shortly after we receive the monetary compensation we may disseminate information about the securities or after we receive the securities, we may sell the securities during the period in which we disseminate information about the securities.
Many of the securities we profile are considered penny stocks. Penny stocks inherently involve high risk and price volatility. You may lose your entire investment in any penny stock that you invest in. You should be acutely aware of the following information and risks inherent in any penny stock investment that you may make, including any issuer profiled on our websites or otherwise:
There is an inherent conflict of interest between our information dissemination services involving various issuers and our receipt of compensation from those same issuers; We may buy and sell securities in the securities that we provide information dissemination services, which may cause: a) significant volatility in the issuer’s stock; (b) price declines from our selling activities; (c) permit us to make substantial profits while we are disseminating profiles or information about the issuer, yet may result in a diminished value to the stock for investors;
Many penny stocks are thinly traded or have low trading volume, which may lead to difficulties in selling your securities and extreme price volatility; Many of the penny stocks we profile or provide information about are subject to intense competition, extreme regulatory oversight and inadequate financing to pursue their operational plan;
The issuer profiles and information we provide represent only a small or even infinitesimal amount of information regarding the issuer and is insufficient to formulate an investment decision; as such, that information should only be a starting point from which you conduct an in-depth investigation of the issuer from available public sources, such as www.sec.gov, www.sedar.com, www.tmxmoney.com, www.otcmarkets.com, yahoofinance.com, www.cnsx.ca, www.google.com and other available public sources as well as consulting with your financial professional, investment adviser, registered representative with a registered securities broker-dealer;
We urge you to conduct an in-depth investigation of the issuer from the above or other available sources, especially because we only present limited information, which is an insufficient basis to invest in any stock, yet alone a penny stock; accordingly, you should proceed with such investigation to determine, among other things, information pertaining to the issuer’s financial condition, operations, business model, and risks involved in the issuer’s business;
You should determine whether the issuer we profile or provide information about is a development or early stage company, which is subject to the risks of a development or early stage company in a similar such business, including difficulties in obtaining financing for operations and future growth;
You should conduct an investigation of the innumerable risks that are inherent or present in the business plan of almost any stock issuer; therefore, do not use our profiles or any information contained in our website or profiles as the sole determination of making an investment decision; We may only present positive information regarding an issuer; therefore, you should conduct an in-depth investigation of any possible negative factors regarding such issuer;
You should accept our information in an “as is” state; in other words, your use of the information is at your own risk and such information may change at anytime and it is not based upon any verification or due diligence of the statements made; The information we disseminate about issuers may contain forward looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, projections as indicated by such words as “expects”, “will”, “anticipates”, “estimates” (other than historical information); therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation into any such forward looking statements;
Forward looking statements are limited to the time period in which they are made and we do not undertake to update forward looking statements that may change at anytime; and We may make statements in our profiles that an issuer’s stock price has increased over a certain period of time since our publication of information about an issuer because such stock price reflects only an arbitrary period of time, it is of no predictive or analytical quality and you should not use any such information in your analysis of any such issuer.
A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in our e-mails/newsletters. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; competition; litigation; loss of key directors, officers or advisors; general economic, market or business conditions; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the applicable regulatory authorities. However, a company’s past performance does not guarantee future results.
Except where prohibited by applicable law, any controversy, claim or dispute arising out of or relating to these terms or your use of the Information will be referred to and governed by and construed in accordance with the laws of the Province of British Columbia, without reference to its rules governing the choice or conflict of laws. The parties hereto irrevocably attorn and submit to the exclusive jurisdiction of the courts of the Province of British Columbia, sitting in the city of Vancouver, with respect to any dispute between the parties.
You expressly understand and agree that in no event will Capital Gains Club, its directors, officers, employees, consultants, advisors or affiliates be liable for any damages whatsoever, including any direct, indirect, incidental, consequential, special or exemplary damages, and any damages for loss of profits, savings, goodwill or other intangible losses, regardless of whether Capital Gains Club has been advised of or could have foreseen the possibility of such damages, arising out of or in connection with the use, inability to use or performance of any of the information provided by Capital Gains Club.
Never base any decision off our website or emails.
Maxtech Ventures continues exploration on Juina claims
Maxtech Ventures Inc (2) (C:MVT)(OTCBB:MTEHF)
Shares Issued 48,786,448
Last Close 5/10/2017 $0.47
Thursday May 11 2017 - News Release
Mr. Peter Wilson reports
MAXTECH DETAILS EXPLORATION PROGRAM ON JUINA CLAIMS IN MATO GROSSO, BRAZIL
Maxtech Ventures Inc. has detailed its phase 1 manganese exploration program on the Juina claims in Mato Grosso, Brazil.
The company initiated its phase 1 exploration program in Brazil on March 3. After an intensive review of the filed National Instrument 43-101 Brasnorte summary research report prepared by John Harper, PGeol, and announced on March 30, groundwork was scheduled on the four Juina claims located north of Juina, Mato Grosso. The claim package totals 39,667.89 hectares in size.
Maxtech's exploration work performed to date focused on claim 866872/2016, part of the Juina claim group. In this area 3 pits were hand dug and samples sent to SGS Geosol Laboratorios LTDA, Belo Horizonte, Brazil for analysis. The 3 assays were received by Maxtech and analyses details were announced by the Company in a news release on April 28th. The samples returned the following assay values; MLB-01 52.9% Mn, MLB-02 55.9% Mn and MLB-03 51.5% Mn. Further to initial pitting there were 16 auger holes drilled covering an area 50 m by 25 m, centered around pit MLB-03. The mineralized horizon occurred from surface to an average depth of 0.6 m. Some peripheral auger holes did not encounter Mn at the surface but are now being followed up with further prospecting and remain open as exploration continues. Pits MLB-01 and MLB-02, located in the same claim, were sampled and also returned high assay values for manganese. These mineralized pits have not yet been followed up. Detailed exploration is on-going.
The Maxtech team is Brazilian based and organized by MLB Mining and Marcio Bastos who has led successful manganese exploration teams for companies in the region. Mr. John Harper B.Sc., P.Geol, who is a Qualified Person with respect to Maxtech's manganese project as defined under National Instrument 43-101 is in charge of all exploration activities for the Company in Brazil.
Peter Wilson, CEO said, "The company's preliminary assay results are fantastic, therefore Phase 2 exploration will be immediately ramped up. The grades of Mn found are directly attributable to our on-the-ground prospecting team in Brazil."
The technical information contained in this news release has been reviewed and approved by Mr. John Harper B.Sc., P.Geol, who is a Qualified Person with respect to Maxtech's manganese project as defined under National Instrument 43-101.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
Streetwise Articles
Biotech/Pharmaceuticals
Critical Metals/Other Metals
Gold
Medical Devices
Oil & Gas
Silver
Special Situations
Tools & Diagnostics
Management Q&A
Resources
Archives
Helpful Resources
Expert Profiles
Analysts
Newsletter Writers
Fund/Money Managers
Sector Experts
Directories
Alliance for Regenerative Medicine
Forbes & Manhattan Group
Neurotechnology Industry Organization
TICKERS: DXD; TDSGF; 3D0
3D Signatures' Platform Taps into the Power of the Genome
Source: The Life Sciences Report (5/10/17)
TDSGF:OTCBB DXD:TSX-V
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment.
Management Q&A: View From the Top
The Life Sciences Report: Thank you for joining us today, Kevin. Can you describe, in layman's terms, 3D Signatures Inc.'s (DXD:TSX.V; TDSGF:OTCQB; 3D0:FSE) TeloView platform and how it works?
Kevin Little: 3D Signatures has a proprietary platform technology that is able to use telomeres, which are the DNA sequences that cap the ends of chromosomes, to establish distinctive profile differences when we look at cells. For example, in the case of cancer, the differences can tell us which cells are going to respond to traditional therapies. In other indications, the pattern of organization of those telomeres tells us whether a patient is likely to progress more quickly down the path of disease. By labeling the telomeres and then using our proprietary technology and software analytics, we're able to build out a panel of different profiles that show us what's going on in terms of the biology within these cells.
TLSR: How is this technology differentiated from other diagnostics on the market?
KL: If we talk about genomics, a lot of companies play in that space. Think about a sort of classical Mendelian genetics, such as what we teach kids in high school about pea plants. We talk about the difference between the genotype, which is the sequence of DNA bases, and the phenotype, which is what the thing ends up looking like. Genotype is the genetics; phenotype is how big a plant grows, what color the flowers are.
I think a lot of technologies seek to get better at linking genotype to phenotype—looking at what's happening at the level of changes in DNA sequence and linking that to biological outcomes like disease or tumor aggressiveness. What I find really compelling about what 3D Signatures' technology does is that we're using these telomeres as a direct biomarker for the phenotype—a pattern that we can immediately show has biological significance.
TLSR: Can you explain the value of targeting the phenotype versus the genotype?
KL: For me, the proof is in the pudding. I think people can spend a lot of time trying to analyze a gene mutation or trying to track how mutations at the genome level actually translate into something you see in a person. To me, what's more relevant is what we see in the patient, what we see that has a clinical significance for people.
Our assay is a way of capturing the instability that goes on as a cell moves from a normal state to something else, something other, and we can monitor these changes dynamically over time. We take that as a snapshot in time, and can say clearly, "Something is happening in terms of the biology here." I've really always been drawn to this question of outcomes—that is what's drawn me into 3D Signatures. The platform can have very profound impacts quite quickly in what it's able to assess at the genetic level in terms of the activity in the cell, and what we see in phenotype, in the outcome with the patient.
The science is quite profound, and Dr. Sabine Mai, 3D Signatures' cofounder and principal inventor, has been able to demonstrate that it applies across many different disease states in a lot of different indications, primarily in the cancers and now also in the neurosciences. The technology has the ability to profile genomic instability, and that gives us a real-time readout of what's happening in that cell within that patient. I think that is profoundly different than what other companies and technologies are trying to do in terms of health outcomes.
TLSR: Are you talking about personalized medicine here?
KL: Absolutely. Running a 3D Signatures test on a patient sample produces a pattern of the organization of the telomeres in each cell that we analyze from that patient. This gives us the ability to inform clinicians how that specific person is likely to respond to traditional chemotherapy (in the case of Hodgkin’s lymphoma), or how aggressively their disease is likely to progress (in the case of prostate cancer). We are empowering patients and doctors to choose treatment options based on their individual status, not a population-wide probability.
TLSR: You're exploring applications in prostate cancer, blood cancers and Alzheimer's disease. Can you explain your methodology for each of these different indications and where they stand in terms of development?
KL: What's really important here is that we have a repeatable platform. By that, I mean we're not reinventing the process for each of the different disease areas we're investigating.
We have a variety of options available to us in terms of capturing the inputs, whether from a cheek swab in neurological indications, or from blood to isolate the circulating tumor cells, or from diagnostic tumor biopsies. But the next steps—in our laboratory processing and then our proprietary analysis software—is really where we've shown refinement, reproducibility and the ability to generate distinct telomere profile differences for many indications and conditions. The robustness and the reproducibility of the platform, time and time again, are really impressive.
So as far as the development time frames, our Hodgkin's lymphoma test is the one that we are focused on right now in a large clinical trial, with the goal to bring that through to market as a laboratory developed test (LDT) in Q1/18.
In prostate cancer, we're involved in the PRECISE trial, and are processing samples from PRECISE recruitment sites as they're coming online. That's going to be a very important trial for us, to be able to benchmark against on a large scale. The next couple of years, as results come out around PRECISE, will be very informative as to the impacts we can have in terms of clinical decisions around screening and monitoring of prostate cancer. We already have plans to engage in a shorter-term look at more aggressive forms of prostate cancer—late stage—and the need for surgical intervention and our ability to predict which patients are suitable candidates, again through a simple blood-based, a liquid biopsy test that we expect to develop over the next one to two years.
TLSR: When can we expect the readout for the prostate trial?
KL: I believe PRECISE goes on for about 24 months. We'll have some evidence along the way, and that's where we see the opportunity to engage in a second, shorter time window.
TLSR: Where is your technology in terms of the approval process? Do you have a timetable as to when you'll begin to start filing applications or marketing products?
KL: With the LDT work in Hodgkin's lymphoma, discussions are underway right now with potential clinical lab partners to bring that test to market. We have quite an impressive group in terms of our business advisory board, which is exploring the regulatory frameworks for that test. We're engaging early on in discussions with regulators to make sure we anticipate things ahead of time.
TLSR: If you were to tell us what the endgame is, can you describe prospects in terms of a partnership or acquisition? Or does 3DS want to take its products all the way to the market on its own?
KL: From a strategy standpoint, the great thing is that all are options, and they're not mutually exclusive. The fact that we have a platform enables us to choose the business models and relationships we believe will best suit the clinical utility of the platform for each indication.
Bringing the test through as an LDT in Hodgkin's ourselves may be the best way to get the product into clinicians' hands to help people. Prostate may be a different market opportunity for us, and if the partnership opportunities are different, we have that kind of flexibility. That is the advantage of having a platform with a lot of different avenues to pursue. Speaking from the scientific and clinical development side, it's a really nice position to be in—to be able to engage in dialogue with potential partners around the best way to move forward together, or to be able to take something to market on our own as the best way to get the product to where it can have the best outcome.
TLSR: What makes 3DS a compelling investment at this point?
KL: There have been some great news stories out there about the company, and we've certainly been growing and bringing on new people, myself included. I've been absolutely amazed by the depth of talent at 3DS. Yes, it's a relatively small team, but in terms of the scientists and clinical lab technologists, I'm not sure I've ever seen this kind of depth and breadth of experience.
I would also point out that we have so much evidence across different indications that demonstrates the effectiveness of the platform, which is exciting. From a clinical impact standpoint, our ability to affect decisions around people's health is incredibly compelling. This isn't just early stage, or theoretical. There's a wonderful breadth of evidence that already shows how this platform has clinical relevance and I think that makes it very compelling for anyone, whether investor, scientific partner or industry partner.
My undergraduate work was in ecology and evolutionary theory, and my graduate work in genetics and genomics—I was even part of a start-up company during my graduate training, where we were trying to develop tests that could characterize how the genome is organized in cells and use that for biomarkers. I went on to do postdoctoral work in translational neurosciences, and looked at the impact of things like the damage chemotherapy can do to cognition. Starting from that sort of ecology-evolutionary background, my perspective has been shaped by time frames and how networks of things interact. The things that really get me excited about what 3D Signatures can do are from that big picture view. 3DS has a big picture view as to what's going on in terms of biology and genomic instability, and how this platform has the ability to have significant impact in so many areas.
And it's moving fast. The people are driven. 3DS really is a wonderful, exciting place to be, and a wonderful opportunity for the stakeholders and partners who are involved with it.
TLSR: Thank you so much, Kevin.
Dr. Kevin Little is the chief scientific officer of 3D Signatures, overseeing the design, development and implementation of the company's research and clinical programs. Prior to his position at 3DS, Little worked as an independent consultant, offering strategic advisory services to help facilitate new life sciences collaborations for public and private sector clients, including Thomson Reuters, Illumina, Janssen, McGill University and the Global Alliance for Genomics and Health. Little previously led the PERFORM Centre, a $36 million health research and community services complex, as the founding chief administrative officer. Before returning to Canada to lead the start-up of the PERFORM Centre, Little spent several years leading the New Zealand government's economic development efforts to build strategic investment relationships across the biotechnology industry sector. Little holds a Bachelor of Science degree in biology from the University of Victoria, and earned his Ph.D. in experimental medicine from McGill University, specializing in DNA repair and functional human genomics.
Read what other experts are saying about:
3D Signatures Inc.
Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new interviews and articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosure:
1) Tracy Salcedo conducted this interview for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this interview: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) 3D Signatures Inc. is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) 3D Signatures Inc. had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Kevin Little and not of Streetwise Reports or its officers.
4) Kevin Little: I was not paid by Streetwise Reports to participate in this interview. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview. I or my family own shares of the following companies mentioned in this interview: 3D Signatures Inc.
5) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts' statements without their consent.
6) This interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
7) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own shares of 3D Signatures Inc., a company mentioned in this article
Maxtech Video Update
http://bit.ly/2p5nOYR
U-MTEHF) - News Release
Maxtech Ventures Reports High-Grade Results from Manganese Project in Brazil - Video Available on Investmentpitch.com
2017-05-05 08:38 PT - News Release
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2017) - Maxtech Ventures (CSE: MVT) (FSE: M1N) (OTC Pink: MTEHF) announced initial high-grade results from its manganese project in Brazil.
Phase I exploration of surface and sub-surface sample results from pitting and auger drilling returned a range of 51.4% to 55.9% manganese. As these are selected samples, they are not necessarily representative of the mineralization.
InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Maxtech" in the search box. The video is also available on YouTube.
Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_5cqo8m0l/Maxtech-Ventures-CSE-MVT-announced-initial-high-grade-results-from-its-manganese-project-in-Brazil
Surface exploration by the company's prospecting team uncovered previously unknown manganese bearing clasts and cobbles.
Peter Wilson, CEO, stated: "Maxtech has now amassed approximately 57,000 hectares of exploration claims in Brazil, which is one of the largest manganese mineral exploration claim sets in the country. In addition to entering our second stage of exploration in Brazil, the Company is actively reviewing potential acquisitions outside of Brazil in Northern Africa and Europe."
Brazil has 10% of global manganese reserves, with manganese being the 4th most widely used metal worldwide. Nearly 90% of manganese output is used in the steel industry, but its applications also include the manufacture of fertilizers, animal food and cars.
Maxtech plans to procure the highest grade possible, which can be used in the Lithium Manganese Dioxide batteries, which contain 4% lithium, 61% manganese and 35% oxygen by atomic weight.
The company announced a non-brokered private placement, and plans to raise up to $2 million through an offering of up to 5 million units at a price of $0.40 per unit. Each unit consists of 1 share and 1 warrant, with each warrant exercisable at $0.50 in the first year and $0.60 in the second year, subject to an acceleration clause, should the shares trade higher than $0.70 for a 14 day period.
The shares are trading at $0.48 and with 45.6 million shares currently outstanding, the company is capitalized at $21.9 million.
For more information, please visit www.maxtech-ventures.com, contact Peter Wilson at 604-330-3119 or email info@maxtech-ventures.com.
About InvestmentPitch Media
Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
Underrated Metal Might Prove Most Bullish Investment for 2017
http://bit.ly/2oC2Sbt
Maxtech Ventures arranges $2-million private placement
Maxtech Ventures Inc (2) (C:MVT) (OTC:MTEHF)
Shares Issued 48,786,448
Last Close 4/27/2017 $0.37
Friday April 28 2017 - News Release
Mr. Peter Wilson reports
MAXTECH ANNOUNCES NEW FINANCING
Maxtech Ventures Inc. has arranged a new non-brokered private placement of up to $2-million.
Maxtech will issue up to five million units at 40 cents per unit, each unit comprising one common share in the capital of the company and one share purchase warrant.
Each warrant will entitle the holder to purchase one additional common share for a period of two years at an exercise price of 50 cents per share for the first year and at an exercise price of 60 cents thereafter. The warrants will be subject to an accelerated expiration period in the event the company's shares trade on a recognized exchange at more than 70 cents for a 14-day period, which will include days where no shares trade, after a period that is four months and a day from the issuance of the warrants.
The proceeds to be raised will be used for working capital and to further the company's plans to acquire additional manganese assets worldwide.
Maxtech has now amassed approximately 57,000 hectares of exploration claims in Brazil, which is one of the largest manganese mineral exploration claim sets in the country. The company's claims are located in the northern states of Mato Grosso and Amazonas.
"In addition to entering our second stage of exploration in Brazil, the company is actively reviewing potential acquisitions outside of Brazil in Northern Africa and Europe," said Peter Wilson, chief executive officer.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
Any update anyone?
Tailwinds Research Group LLCTailwinds Research Group
3D Signatures: Disruptive Technology with an Attractive Business Model
By Daniel Carlson - April 21, 2017
At Tailwinds, we are focused on finding future leaders. Companies that fit our model bring new technologies to growing markets. The combination of disruptive technologies with expanding end markets gives our portfolio companies the opportunity to grow at multiples of the overall economy and command premium valuations. 3D Signatures (3DS) is one of those companies.
Genomic Analysis for Personalized Medicine
In 2003, after more than a decade of research, the Human Genome Project was completed by the U.S. Department of Energy and the National Institutes of Health.
The goals of the Human Genome Project were to learn the order of the 3 billion units of DNA that go into making a human genome, as well as to identify all of the genes located in this vast amount of data. By 2003, almost all of the pairs of chemicals that make up the units had been put in the correct sequence—enough for a pronouncement of success.
The information garnered from the genome project has the potential to forever transform healthcare. Many believe that genome-based medicine, frequently called personalized medicine, is the future of healthcare—the next logical step in a world in which more is known about human genetics, disease, and wellness than ever before.
Personalized medicine is a young but rapidly advancing field of healthcare that is informed by each person’s unique clinical, genetic, genomic, and environmental information. Because these factors are different for every person, the nature of diseases—including their onset, their course, and how they might respond to drugs or other interventions—is as individual as the people who have them.
Personalized medicine is about making the treatment as individualized as the disease. It involves identifying genetic, genomic, and clinical information that allows accurate predictions to be made about a person’s susceptibility of developing disease, the course of disease, and its response to treatment.
In order for personalized medicine to be used effectively by healthcare providers and their patients, these findings must be translated into precise diagnostic tests and targeted therapies. This is where 3D Signatures comes into the picture.
With their unique diagnostics centered around Telomeres, a protective structure that safeguards chromosomes and insures genomic stability, 3DS has discovered a platform with the potential to provide advanced diagnostic results for many diseases, allowing personalized therapies to be delivered to the patients.
“Our novel, proprietary technology analyzes a specific part of an individual’s unique DNA (their telomeres) to determine how a disease will progress and if a patient will respond to treatment. This information enables clinicians to measure the appropriateness and effectiveness of different treatments for specific patients.”
This is groundbreaking research with the potential to provide both better patient outcomes and significant savings to the healthcare system. As an example of how this works, examine the results from 3DS’s recent assay validation study related to Hodgkin’s Lymphoma, a disease for which the standard of care is chemotherapy and in which 20% of patients suffer a relapse.
Powered by the Company’s proprietary TeloView™ software platform, the test stratifies HL patients at the point of diagnosis into non-relapsing and relapsing patients. Relapsing patients may then be considered for alternative treatments at the time of diagnosis rather than waiting until they have failed multiple rounds of standard chemotherapy.
Avoiding multiple failed chemo treatments not only is of obvious benefit to the patient, but can result in savings of over $90,000 per treatment that is avoided. At this time, there is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients. 3DS is hoping to change this and will launch their clinical trial soon, in an effort to be first to market with a successful diagnostic.
And, it’s not just Hodgkin’s Lymphoma. TeloView™ is a platform that has potential applications in many diseases. The above chart shows 3DS’s progress in discovering biomarkers in several forms of cancer as well as Alzheimer’s; as you can see, they are already progressing on multiple fronts and this is just a partial list of potential applications. The Company already believes the technology has potential in 12 kinds of cancer, and expects that number to only increase.
Diagnostics With a SaaS Model
To date, 3D Signatures has demonstrated success in many early stage trials. This has enabled them to obtain financing, not only in the public markets, but through significant, non-dilutive, grants as well. It has also sparked the interest of many large pharmaceutical companies, which, according to the Company’s recent press release, might fund them “through non-dilutive or independent financing arrangements, such as a joint venture.”
Joint ventures would make a lot of sense for 3DS as they could partner on many diseases, thereby increasing their pipeline, without diluting investors. However, the broad applicability of their platform would make an acquisition less likely, in my opinion, as their technology could help assay a far broader swath of diseases than any one pharma company would be attacking.
Thus, I fully expect 3DS to be coming to market with their own assays in the future. Which brings up another very positive aspect of their business. Besides being potentially able to assay many different diseases, the model is incredibly high-margin, scaleable, and protected on the IP. This is due to their SaaS model of performing assays.
The assays analyzed by 3D Signatures are all collected elsewhere, at outpatient centers or in the hospital labs. Once prepped, they are shipped to 3DS for analysis. 3DS has a very intense three dimensional imaging program that examines each sample and returns back the data needed to diagnose diseases, their stage, progression, etc., with those results then returned to the patient’s physician.
The important part, from the business model perspective, is that 3DS is simply running a software diagnosis on samples that are collected and prepped elsewhere. It’s kept in house to control the proprietary nature of the program, but the majority of the labor is external. This creates a very high margin and scalable Software-as-a-Service (SaaS) model for 3DS.
This high margin, scalable model is a key differentiator for 3DS. As they grow the number of assays performed, the company’s bottom line will expand rapidly. The SaaS model is one that typically gets rewarded with a much higher multiple by the market, due to the upside potential, as well as the high margins which limits losses should business slow for any reason.
A Disruptive, Scalable Platform
The bottom line here on 3D Signatures is that this company represents everything that we at Tailwinds are looking for in our Select Portfolio companies. They have a highly disruptive business, being able to (hopefully) perform diagnostics on diseases that haven’t been accurately diagnosed, from a personalized medicine perspective, in the past. By doing so, the Company provides a benefit to patients and a much needed cost savings to the whole healthcare system.
Meanwhile, they are doing this with a high margin, scalable software model that will allow them to be highly profitable if and when their business takes off. And, finally, their technology is a platform with broad applications within the medical field; a platform which has yet to fail in a clinical trial. Put together, 3D Signatures represents a compelling investment opportunity.
Wealth Research Group Interviews Kootenay Zinc Corp's Tookie Angus
How to find a buttload of zinc: First, you miss, then you miss less
Chris ParryApril 18, 20170
zinc
Okay, mining newbies, we’re going to play a little resources 101 today, because some interesting stuff is happening out there in the big bad world that may necessitate your learning something outside of the weed market.
Master Trump, the first Presidential boy, is making noises like he’s going to slap away on the nuclear football until it makes a big banging noise, and if that happens, you’ll want to know what mining is.
That’s not easy for someone on the outside, as mining comes with loads of terms, assumed knowledge, and what ifs that require some book learnin’.
Or a guy like me to explain.
So today we’re going to look at zinc, because this:
zinc stocks
zinc year
Goldman Sachs forecast a 114k ton shortage of zinc in 2016 which it said would widen to 360k tons in 2017. For the first time last year, China, despite being the world’s largest producer of zinc, was forced to import it.
Now, I’m not going to say there’s no zinc left in warehouses scattered about the globe, but there’s a lot less of it out there than is ideal, because zinc is usually extracted as a secondary ore in copper mines.
Say hi to copper.
spot-copper-5y-Large
Copper, you’re adorable, we love you, but get your shit together.
Added to that, 5 million tonnes of zinc a year are yanked out of China. The next biggest in the world is Australia, with 1.5 million. From there it’s a freefall. Basically, China has all the zinc, and if President Cheeto decides to pick a fight with them, or they decide to shit down a few mines to alleviate environmental problems, oh boy.
So with copper on the dropsies, as copper mines roll out of active use and new mines are deferred until they’re more profitable options, and existing supplies tied up in potential political weirdness, what happens to zinc?
Well, smart folks go looking for it.
The Kootenay Zinc crew are smart folks.
The Teck Resources Sullivan mine was a beauty. A $49 billion beauty. It yanked 337 million ounces of silver out of the ground, and 17 million tonnes of lead and zinc as a rich by-product. It’s classified as ‘legendary’ status.
On the map below, it’s right next to the town of Kimberley, in the Kootenay BC region.
sullivan
Over on the other side of that map is Fort Steele. That’s where Kootenay Zinc has decided to play.
Here’s what that map looks like if you’re an earthworm.
kootenay regionNow, I know that looks a little complex, but here’s the skinny: On the left is Sullivan. That blob of red under it is that legendary mine. If you track the red along, you find where it came from; a big old schism of fault lines. One big chunk o’rock went west, towards Kimberley, while another when up, towards Fort Steele.
The Sullivan vein was easy to hit because it was close to surface, fat, and horizontal. The Fort Steele stuff? That’s going to take some tech know-how to hit.
Gravity_MapArtboard_34x_Compressed-ID-0dccbe5e-c281-484a-8b39-2b6ef548fd93
How does ZNK know there is ore to be had way underground? Well, geologists scour the surface to find signs of it, then they do aero-magnetic imaging, by flying a plane over and measuring magnetism below, or with gravity measurements.
Rapid and huge diurnal variations may arise unpredictably due to an extraterrestrial, solar wind of charged particles. The magnetic field itself is dipolar and usually non-vertical. Rocks can be magnetized in a vast and unpredictable variety of ways, induced or remanent, primary or secondary. Magnetization can be altered and lost when rocks are heated, reacquired when rocks cool, and created, destroyed or changed due to chemical alteration and other processes.
Gravity readings on earth are not the same everywhere. The planet’s rotation and polar flattening are well known and easy to correct for, as are the small and predictable diurnal variations due to tidal forces of the Moon and the Sun. After these and other corrections, we are interested in map-scale gravity variations attributable to lateral changes in the density of local rocks.
So ZNK flew over the area and got some imaging that indicates there’s rocks as laid out in the map above.
From the Kootenay Zinc website:
A Cominco airborne geophysical survey identified two N-S trending magnetic anomalies underground at Sully. These are up to 3 km long, about 1 km apart and are near-coincident with the gravity anomalies.
That’s tasty.
The next step from there will be to stick drills in the most likely areas to find ore. Cominco chucked a couple down back in the day and managed to dodge everything. Those are the dotted lines below.
Gutterball!
Drill_SiteArtboard_44xCompressed-ID-febd3adc-3624-4d59-ed92-a2a7bd68813f
So Kootenay likes that the first drill attempts missed, because if they hadn’t, there’d be no way for this company to get its hands on a property that could well be something glorious.
So they went hard after that east mass and tossed another drill down.
The result?
The Sully project team has recently completed drill hole SY17-11, which tested a portion of the E1 zone of the East anomaly. The hole did not intersect an extensive high density mass but did intersect a number of geologically significant features with similarities to the Sullivan sedimentary environment.
Another gutterball. But that doesn’t mean nothing’s down there. It means the team has a better idea now of where the big vein isn’t, which helps lead it to where that mass may be.
But that miss is a big part of why the share price for ZNK, which had gone so ballistic early this year, from $0.10’s to $0.60’s, suddenly went the other way back to the $0.20’s.
That doesn’t suck for you, however, if you’re yet to buy the stock. Because now you get value.
First? More magnetic, and in closer gaps.
The geophysical interpretation has greatly benefited from increased and closer spaced gravity stationing that has provided better definition of the anomaly. The new modeling also shows how and where the previous drill holes missed the E1S target as we know it now. The new close spacing of gravity field stations at E1S made it possible to generate three dimensional equivalent mass models for the first time on any of the anomalies at Sully.
The E1S model indicates the mass has a strike length of about 150 metres and that it is truncated at its north and south ends. It also shows that the target extends from a depth of approximately 70m to 270m below surface – but the target may well continue to depths below 270m.
So what? I see you, you naysayers, you cynics, saying ‘they didn’t hit anything, this is a bust.’
And to that I say, bullshit. Look, the perfect situation on a junior explorer is for them to miss the first batch, the share price heads to the basement, and then you get in while it’s oversold. Kootenay Zinc, for mine, is way oversold.
The rush on the stock began in part because of who’s involved, not what they’ve got. Ladies and gentlemen: Mr Tookie Angus.
Mr. Angus is an independent business advisor to the mining industry. Mr. Angus is the former chairman of the board of B.C. Sugar Refinery Ltd. He was a director of First Quantum Minerals until June, 2005, a director of Canico Resources Corp. until its takeover by CVRD in 2005, and a director of Bema Gold until its takeover by Kinross Gold in 2007. More recently, he was managing director of mergers and acquisitions for Endeavour Financial, a director of Ventana Gold until its takeover by AUX Canada Acquisition in 2011, and a director of Plutonic Power until its merger with Magma Energy in 2011. He is currently chairman of [the $1 billion market cap] Nevsun Resources Ltd. (NSU.T), which operates one of the highest-grade open-pit copper mines in the world. He is also the current chairman of [the $120m market cap] K92 Mining Inc (KNT.V).
Ladies and gentlemen: Mr Peter Meredith:
Mr. Meredith has been a director of [the $3.8 billion market cap] Ivanhoe Mines Ltd. (IVN.T) (formerly, Ivanplats Limited) since May, 1998. Mr. Meredith is the former Deputy Chairman and Chief Financial Officer of Ivanhoe Mines Ltd. (now Turquoise Hill Resources Ltd.), where he was involved in overseeing Ivanhoe Mines Ltd.’s business development and corporate relations. Mr. Meredith was member of the board of directors of Ivanhoe Mines Ltd. and also served as its Chief Financial Officer from June, 1999, to November, 2001 and from May, 2004, to May, 2006, and as its Deputy Chairman from May 2006 to April 2012. Mr. Meredith was also Chairman of South Gobi Resources Ltd. until September, 2012.
By all means, be skeptical of any junior miner. But when you do your due diligence, stopping at the most recent drill hole news release is a dumb play, because guys like this don’t play in the shallow end of the stock pool.
On the technical side? Local knowledge:
[CEO Paul] Ransom is a geologist and noted Sullivan SEDEX deposit expert, having worked for over 33 years with Cominco, now Teck Resources Limited. Much of his career was spent at Sullivan related to the regional geology. Mr. Ransom has authored and/or co-authored ten papers on geology of the Sullivan deposit.
Ten years studying the geology of this region, 33 years running geo for Cominco/Teck. If knowing the geology of the Sullivan region were an Olympic event, Ransom would be the captain of Team Canada.
Now, I’m not going to tell you that anyone is slapping a drill right through a bonanza tomorrow, or even next month. Maybe not for a year, maybe never. But if you’re talking a sector on the charge, which we are, and an area play in an area that is ‘legendary’ for this metal, which we are, and with people who are legends in the business, which we are, and a CEO who knows more about this plot of rock than anyone – which we are… I think that’s interesting, and bears watching.
Me? I’m underwater on the stock – fair disclosure. But I’m holding it, because the dumbest time to sell is when everyone else already has. That’s when you go get your value on a deal you’ve done your digging on.
If ZNK misses on the next hole, well you’ve got to ask questions at that point. But many great discoveries started with a couple of whiffs. I’m in.
— Chris Parry
FULL DISCLOSURE: I am a stock owner in Kootenay Zinc.
3D completes validation of Hodgkin's lymphoma test
3D Signatures Inc (C:DXD) (OTC-TDSGF)
Shares Issued 46,445,199
Last Close 3/28/2017 $0.71
Wednesday March 29 2017 - News Release
Mr. Hugh Rogers reports
3D SIGNATURES COMPLETES ASSAY VALIDATION FOR HODGKIN'S LYMPHOMA TEST
3D Signatures Inc. has successfully completed internal analytical assay validation for its Hodgkin's lymphoma (HL) test (Telo-HL) pursuant to Food and Drug Administration guidelines. Assay validation of Telo-HL included validating the consistency of key reagents and the reproducibility and repeatability of the locked protocol. This process is referred to as stage 2 of the validation program as set out in the company's news release dated Feb. 23, 2017. Assay validation was completed on schedule.
Powered by the company's proprietary TeloView software platform, Telo-HL stratifies HL patients at the point of diagnosis into non-relapsing and relapsing patients. Relapsing patients may then be considered for alternative treatments at the time of diagnosis rather than waiting until they have failed multiple rounds of standard chemotherapy. There is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients.
The company expects Telo-HL to benefit patients seeking personalized treatment while also providing significant cost savings to payors and insurers that are currently burdened with expensive treatments and procedures that may not be necessary if patients could be considered for more targeted and effective therapies at the outset.
"The data collected during this validation stage confirms that the Telo-HL assay is reproducible according to FDA guidelines for clinical quantitative assays," stated Dr. Oumar Samassekou, 3D's vice-president of clinical technology. "We are ready and excited to launch the clinical trial to develop and finalize the scoring model for Telo-HL. This will establish a score to delineate relapsing from non-relapsing patients at the time of diagnosis, before they begin first-line chemotherapy."
The clinical trial will commence in the coming weeks and include the analysis of 250 to 300 retrospective HL patient samples that match the targeted prognostic criteria for the test. A statistical scoring model will also be developed and finalized from the data collected during the clinical trial. The clinical trial is expected to be complete in less than five months.
About 3D Signatures Inc.
3D Signatures is a personalized medicine company with a proprietary software platform based on the 3-D analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
Investor Relations
1-604-428-8842
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
Manganese – The Third Electric Vehicle Metal & No One Is Talking About It! Here’s How To Take Advantage
Palisade Research March 24, 2017
Category: Research
A Brief Manganese Primer
Highlights
• Manganese is a critical and irreplaceable element used in steel production;
• The steel industry is poised to continue growing, providing a steady source of demand for manganese;
• Significant additional upside will come from clean-energy applications;
• Vertically-integrated companies will be primary drivers of the forward momentum in the manganese industry, which at this point is concentrated and in need of disruption.
Lithium and cobalt have been on an absolute tear, riding the wave of Tesla and the broader electric revolution. There is another metal, however, used widely as a battery component that has received less notice from the markets. That metal is manganese (Mn), a chemical element that is normally found together with iron.
Since the beginning of 2016, cobalt’s price has jumped 120%, lithium has moved up 77%, and manganese has recorded a 42% gain. While all three metals have seen their prices rise recently, it appears that manganese has been outshined by its two fellow EV metal counterparts. We believe this situation will change quickly, as demand for manganese is set to outpace supply, especially for higher-grade materials found only in specific corners of the globe.
Introduction – Manganese Is Critical
Manganese is an essential ingredient steel. And according to the US Geological Survey’s (USGS) Mineral Resources Program, the United States is completely dependent on manganese imports; it has no production facilities of its own. The US needs about 500,000 tons (1.1 billion pounds) of manganese per year, the majority of which is consumed by the steel industry.
Acutely aware of this situation, and the fact that most of the world’s manganese is produced by just a few countries (some of which are risky jurisdictions), the USGS has deemed manganese a “critical mineral.” A critical mineral is one defined as being essential to the economy, as well as being at significant risk of incurring supply interruptions. The USGS has also singled out manganese because of its importance due to its increasing use in emerging technologies.
Solid Growth in Demand
In steel production, manganese serves the important function of removing oxygen and sulphur when iron ore is converted into iron. It is also used as an alloy that increases both the strength and flexibility of steel. In ore production, about 30% of the manganese is used to refine ore and about 70% is used as an alloy in the final product.
Manganese is not on the radar of many investors, but it is widely used in metallurgy. In fact, it is the fourth most commonly used metal by tonnage – after iron, aluminum, and copper. And during the past ten years, the world has generally produced increasing amounts of steel every year.
Between now and 2020, the International Manganese Institute projects that the global steel industry will continue growing at a clip of about 2% annually.
The United States is expected to lead the way in 2017, with a projected 4.4% increase in steel production. This number is expected to surge even further as President Trump turns his attention towards pushing legislation for a $1 trillion infrastructure plan.
In addition to the steel industry, manganese is also utilized in animal feed and fertilizers, two sectors with demand that will continue to grow in concert with the world’s population.
Moving forward, we see significant growth in the manganese market due to its applications in clean energy. More specifically, we anticipate the growing use of nickel-metal hydride (NiMH) electric vehicle batteries and lithium-ion (Li-ion) batteries to be major catalysts for manganese demand. NiMH batteries are predominantly used in hybrid vehicles, including the Toyota Prius. The Li-ion battery, of course, takes center-stage due to Tesla’s notoriety and lofty production targets.
The newest up-and-coming technology to use manganese is the so-called lithiated manganese dioxide (LMD) battery. A typical LMD battery uses 61% of manganese in its mix and only 4% lithium. LMDs have numerous benefits, including providing higher power output, thermal stability, and improved safety compared to regular lithium-ion batteries.
LMDs are already in production, and are currently used in electric cars like the Chevy Volt and Nissan Leaf. These cheaper electric cars, as opposed to the narrower luxury-segment that Tesla operates in, should be a significant part of the budding clean energy revolution.
Finally, there is a game-changing application of manganese worth mentioning: off-the-grid power. Tesla and its Powerwall batteries are breaking ground here, and the market is only poised to grow.
(Credit: Inside EVs)
In summation, there are several drivers that should boost manganese demand, both traditional and cutting edge.
Manganese will continue to be a key element in steel production, and the industry should continue to grow at a steady pace. Steel production will ensure that manganese remains as one of the most widely used elements in the world. On the technology side, electric vehicles, off-the-grid power systems and other energy storage applications will require significant amounts of high-quality manganese.
Risky Business On The Supply Side
Most manganese production globally is concentrated in four countries: Australia, China, Gabon, and South Africa. 90% of the world’s manganese reserves are found in these four countries, along with Brazil and Ukraine. Remarkably, nearly 70% of global manganese reserves are contained in the Kalahari District of South Africa.
(Source: USGS)
South Africa’s deposits tend to be high-grade. Australia, Gabon, and Brazil, however, feature even higher grade deposits. This bodes well for the explorers and developers operating in these countries.
(Source: Manganese.org)
In the United States, there has not been any manganese mining activity since 1970. There are a few areas where it is possible to find manganese-enriched rocks (Maine and Minnesota), but the grades are substantially lower than what is available around the globe, so mining manganese in the United States does not make economic sense. As a result, the U.S. imports all of its manganese.
61% of the United States’ manganese imports come from Gabon. Australia is the second-largest provider of manganese to the U.S., with 21% of the total. South Africa (7%) and Brazil (5%) are the third and the fourth largest manganese exporters to the United States.
China, meanwhile, is the world’s number two producer of manganese and also one of its largest consumers. Demand for imported manganese ore in China more than doubled between 2006 and 2016. As of 2016, almost two-thirds (62%) of manganese ore in China was imported. The gulf between manganese production and consumption in China has been widening since 2001.
China, like the United States, imports most of its manganese from South Africa, followed by Australia, Gabon, and Ghana.
Unlike steel, where demand is notoriously steady, the supply of manganese is declining. In 2016, the USGS estimated that the world produced 8.6% less manganese than in 2015.
(Source: USGS)
This is one of the imbalances that resulted in the recent upward price action in manganese. The price of manganese has risen over 42% since the beginning of 2016.
The estimated demand for manganese in 2022 is forecasted to reach 28.2 million metric tonnes. Compare this to historical rates of manganese production, which peaked in 2014 at 18.0 million MT. Clearly, the widening gap between supply and demand in the manganese space should lead to a healthy price increase over the next few years. We believe that one manganese explorer, in particular, is poised to take advantage of this dynamic, and its management team already has one exit under their belt in the manganese sector.
Maxtech Ventures Inc. (CNSX:MVT, FRA:M1NA, OTCMKTS:MTEHF)
Current Price: C$0.60
Shares Outstanding: 48.7 million
Market Capitalization: C$29.2 million
52-Week Range: C$0.12-C$0.63
Cash: ~C$0.6 million
Total Liabilities: ~C$0.1 million
Maxtech Ventures is advancing work on several high-grade manganese projects in Brazil. All of the company’s projects are located in Brazil, but Maxtech is focused on seizing the opportunity to become a global supplier, with customers in Europe, North America, and Asia.
(Source: Maxtech)
The company’s aim to sell manganese products globally rests on the existence of high-quality infrastructure in the regions where it operates. Looking at this map, it may appear that the company’s projects are located in remote areas, however, the reality is that Maxtech has access to multiple high-volume commercial river ports. Additionally, a major regional road is slated to be constructed within a couple of years.
Maxtech is focused on the Brazilian region of Mato Grosso. The area has seen much less exploration and production than the neighboring Rondonia region; nonetheless, both regions have similar geology. Between Mato Grosso and Rondonia, known manganese mineralization extends across a belt of at least 250 kilometers. Most of the mineralization lies at surface, with reported grades reaching 54% or higher. These high-grade veins extend to over 80 meters in depth.
Since so much of the material is available at surface, mining it is not an expensive enterprise. The technical flow sheet for the production of manganese in the Eastern Rondonia/Western Mato Grosso region is very simple.
(Source: Maxtech Ventures)
This technical simplicity allows for cost control that is not possible for more complex methods of production. It is also one of the reasons why Maxtech believes that it can successfully compete in the global manganese market. Low production costs and increasing prices should allow Maxtech to generate healthy margins in the future.
Lastly, Mato Grosso is an area known for soybean production, and manganese-based fertilizers are widely used there. It can only be to Maxtech’s benefit to operate in close proximity to prospective end-users of its product.
Exploration
Exploration costs for Maxtech should be quite modest, since most of the manganese in this region of Brazil is located at surface. It is rather a matter of scope, not depth, that Maxtech needs to worry about.
(Source: Maxtech Ventures)
With this in mind, Maxtech recently announced an exploration program. The program will include early-stage activities, such as prospecting, mapping, geochemical soil surveys, and ground-based geochemical surveys.
At Mato Grosso, there are two types of manganese mineralization – cobbles/clasts and hydrothermal veins. Maxtech will need to calibrate its exploration methods to study and understand both types of mineralization.
Most of the program can be completed using relatively inexpensive methods, including hand-dug pits, mobile auger drills, and trenching.
For us, it means that the company will be able to advance its understanding of Mato Grosso geology quickly and efficiently. When preliminary targets are identified, Maxtech will follow-up its green field exploration activities with traditional core drilling.
Near-Term Production
Maxtech is also very active on the acquisition front. Earlier in March, the company signed a Letter of Intent (LOI) to form a joint venture partnership to develop the Buriturama Mine in the State of Bahia, Brazil with Plantiminas Empreendimentos Rurais Ltda.
The mine has existing access to railway, ports, and other infrastructure. The aim is to advance the Buriturama towards mining with a goal of generating 10,000 tonnes per month in production. The project already has a trial mining license for the processing of up to 6,000 tonnes of manganese mineralization. An application has already been submitted for a Lavra license, which would provide for unlimited mining activities at Buriturama.
One of the key features of Buriturama is its proximity to Mina do Azul, operated by Vale SA. Mina do Azul has manganese concentrations in the range of 40% and higher. Buriturama’s historical records (non-NI 43-101 compliant) indicate that its ore contains similar grades. Between regional-scale exploration programs and advancing Buriturama to production, Maxtech is engaged in building a vertically integrated manganese producer.
The company is also keenly aware of the multiple markets that its manganese products could serve. From local agriculture companies, which need manganese fertilizers to produce soy, to the global high-technology battery market, Maxtech has the potential to sell its production far and wide.
Vision – Replicating A Proven Model
This vision comes from the company’s seasoned management team. Maxtech is led by Mr. Peter Wilson, a financier with over $300 million in equity and debt financings under his belt. He has been involved in capital raising, corporate development, and management for over 20 years.
On the technical side, Maxtech’s project acquisition and exploration activities are overseen by the same team behind Cancana Resources.
Cancana’s flagship was the BMC Project, located in state the of Rondonia. As part of a joint venture on the project, Cancana was partnered with Ferrometals, an investment vehicle for the resource-focused private equity fund, The Sentient Group, which at the time had US$2.7 billion in assets under management. Cancana was eventually acquired by Ferrometals and in turn listed as Meridian Mining (CVE:MNO). Meridian Mining now boasts a market cap approaching CAD $100 million.
When the acquisition closed in November 2016, the original team from Cancana went right back to work, looking to replicate the same model.
With the experience that its CEO brings to the negotiating table, along with the expertise of its technical team in Brazil, there is good reason to believe that Maxtech can transition from explorer into producer and create substantial value for its shareholders.
Capital – Ready To Produce
Maxtech’s impending exploration program is a direct consequence of a financing that management arranged earlier in 2017. This $607,500 capital infusion is part of a larger financing effort that the company is undertaking. The plan is to spend most of the funds raised on its Brazil operations, plant engineering, and the preparation of a NI 43-101 report.
Maxtech’s financing push is backed by positive economic projections for the company’s near-term producing properties. The company forecasts that it can start production later in 2017 at a rate of 6,000 metric tons, moving to production of 26,500 tonnes by 2018, and ramping up to 67,000 tonnes by the end of the decade.
(Source: Maxtech)
The company is close to reaching production stage, which will help it afford to continue purchasing prospective claims and projects in Brazil.
As a result of the company’s well-outlined focus and position in the middle of a manganese renaissance, we anticipate increased investor interest and significant share price upside. We expect continued momentum in the next twelve to eighteen months in response to hitting several of its key milestones.
3D's TeloView can identify Alzheimer's patients
3D Signatures Inc (OTCQB:TDSGF)(C:DXD)
Shares Issued 46,445,199
Last Close 3/20/2017 $0.67
Tuesday March 21 2017 - News Release
Mr. Hugh Rogers reports
3D SIGNATURES' TELOVIEW SOFTWARE IDENTIFIES AND STAGES PATIENTS WITH ALZHEIMER'S DISEASE FROM A CHEEK SWAB
3D Signatures Inc. has provided clinical study results which confirm that based on a swab from the inside of a patient's cheek, its proprietary TeloView software platform has the ability to identify patients with Alzheimer's disease (AD) and, furthermore, distinguish between mild, moderate and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer's Disease.
AD is the most common form of dementia affecting approximately five million Americans age 65 and older, as well as an estimated 200,000 Americans under the age of 65 who are afflicted with early-onset AD. AD is clinically defined as a progressive neurodegenerative disorder that involves cognitive impairment, memory loss, visual-spatial retrogression and language impairment. AD is the fifth leading cause of death for people age 65 and older.
"Current diagnostic methods are not highly specific," commented Dr. Sabine Mai, 3DS co-founder and principal inventor. "In addition, AD is only confirmed postmortem pathologically. There is a significant need for an accurate, non-invasive biomarker that can diagnose AD and indicate disease progression, and we believe TeloView{A } has the potential to answer that important call."
In agreement with previous research, the current study demonstrated that TeloView{A } software platform clearly distinguished between AD and non-AD individuals, and between mild, moderate and severe AD, and is, therefore, a promising candidate as a non-invasive AD biomarker and monitoring tool. The current confirmatory study involved a cohort of 44 age- and gender-matched healthy non-caregiver controls and 44 AD study participants. 3D telomeric profiles of buccal cells of AD patients and their non-AD controls were examined with participant information blinded to the analysis.
The Company is currently exploring opportunities to expand the scope of its AD related work with further clinical studies and to fund that work through non-dilutive or independent financing arrangements, such as a joint venture.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
Kootenay Zinc completes structural review of Sully hole
2017-03-20 06:27 PT - News Release
Shares issued 22,064,294
ZNK Close 2017-03-17 C$ 0.54
Mr. David Schmidt reports
KOOTENAY ZINC CORP. ANNOUNCES FURTHER UPDATES ON SULLY PROJECT
Kootenay Zinc Corp.'s Sully project team has recently completed a structural review of a portion of drill hole SY17-11. Specifically, core recovered in the modelled position of the E1 gravity mass of the east target was assessed. As described in previous news, the hole did not intersect an extensive mass in this position, but did intersect a number of geologically significant features with similarities to the Sullivan sedimentary environment.
Oriented core was obtained while drilling that allowed structural orientations of planar features (such as bedding, cleavage, veins, faults and dikes). The core and the feature must be reasonably intact to achieve an orientation. The data collected and logged in SY17-11, within the E1 zone of interest, form the basis for the following structural review.
At hole depths corresponding to the projected E1 gravity anomaly, several gouge-filled faults and broken zones are noted. The gouge zones range from two centimetres to 10 centimetres thick, some with associated core loss. However, it was noted the faults are commonly developed parallel to cleavage (dipping about 40 degrees west-northwest). Bedding above and below this interval is generally uniform and typically overturned; throughout the zone bedding is tightly folded and is repeatedly offset on cleavage planes. The folds appear to be symmetric, indicating a larger-scale fold-flexure developed across the entire zone of interest. Movement during folding caused rocks at higher levels to be shifted east of rocks below them on reverse-type faults.
Because the strata are steep to overturned, the offsets would have created gaps or fault windows, and it is possible that SY17-11 passed from west of the zone of interest (and above such a fault) to east of it (below the fault). This structural possibility will continue to be evaluated as it provides an explanation that the E1 gravity anomaly is in proximity to the recently completed drill hole.
Modelling and interpretation of all the new geological and geophysical data are intended to assist in determining where, and at what depth, the E1 anomaly is likely to be found. The location and orientation of the next drill hole will be based on this information. The project team is also currently completing its review and modelling of new ground magnetic survey data recently collected over much of the extent of the gravity anomalies and of fill-in gravity data in the E1 anomaly area. The results of that work will be reported shortly.
About Kootenay Zinc Corp.
Kootenay Zinc is a mineral exploration and development company that is presently targeting the Sully property. The company is focused on discovering large-scale sedimentary-exhalative deposits.
The Sully property comprises 1,375 hectares located approximately 30 kilometres east of Kimberley, B.C., and overlies rocks of similar age and origin as those which host the world-class Sullivan deposit, owned by Teck Resources Ltd. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, eight million tonnes of zinc and eight million tonnes of lead.
The scientific and technical information contained in this news release has been reviewed and approved by the company's project manager, Paul Ransom, PGeo, a qualified person as defined in National Instrument 43-101, standards of disclosure for mineral projects.
We seek Safe Harbor.
Correction:
Maxtech Signs Letter of Intent to Form JV on Licenced Manganese Buriturama Mine in Brazil
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 16, 2017) - A correction from source has been issued for the release disseminated March 16 at 3:15 AM ET. The complete and corrected release follows:
Maxtech Ventures Inc. (CSE:MVT)(CSE:MVT.CN)(OTC PINK:MTEHF)(FRANKFURT:M1N) , ("Maxtech" or the "Company") has signed a Letter of Intent ("LOI") to form a joint venture to develop the Buriturama Mine in the State of Bahia, Brazil with Plantiminas Empreendimentos Rurais Ltda.
***At the request of IIROC the Company wishes to clarify specific disclosure in its March 16, 2017 news release. Readers should disregard the disclosure in the earlier release.
The Buriturama Mine is located in the northern portion of the State of Bahia, 862 km from Porto de Aratu with access to railroad, port facilities and infrastructure. The Buriturama Mine has significant historical mining records as well as a current Gia (trial mining license) which authorizes mining and processing of mineralized materials. Small scale mining has been undertaken on the project and there are outcrops located throughout the project area as well as mining pits. An application has been submitted to Departmento Nacional de Proucao Mineral ("DNPM") for a Lavra licence which provides for unlimited mining. The company will do both technical and legal due diligence on the asset prior to signing a definitive agreement.
Vale's Mina do Azul Mine is situated approximately 100km's north of the Buriturama Mine in Bahia, and is responsible for a large percentage of Vale's manganese output. Vale SA is the largest manganese producer in Brazil and the Mina do Azul Mine is recognized internationally for its mineralized materials which contains high concentrations of manganese and a high manganese-iron ratio.
The markets for manganese mineralized materials and ferroalloys are highly competitive. High-grade manganese competes on a global seaborne basis while low-grade mineralized materials competes on a regional basis. The ferroalloy market is characterized by a large number of participants who compete primarily on the basis of price. The competitive factors affecting this market are the costs of the mineralized materials, electricity, logistics, and reductants.
Peter Wilson, Maxtech CEO, said, "We will begin the due diligence process immediately. The Plantiminas Empreendimentos Rurais Ltda. strategic partnership in the Buriturama Mine will enable Maxtech to build vertical manganese operation in Brazil."
The Company also announces that pursuant to its stock option plan it will issue 1,000,000 options to certain officers, directors and consultants at a price of $0.57 cents per share. The options granted are exercisable up to five years from the issue date.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
For additional information see the Company's web site at http://www.maxtech-ventures.com.
Further information about the Company is available on www.SEDAR.com under the Company's profile.
Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Maxtech Ventures Inc.
Peter Wilson
Chief Executive Officer
604-484-8989
peter@maxtech-ventures.com
info@maxtech-ventures.com
www.maxtech-ventures.com
Maxtech Signs Letter of Intent to Form JV on Licenced Manganese Buriturama Mine in Brazil
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 16, 2017) - Maxtech Ventures Inc. (CSE:MVT)(CSE:MVT.CN)(OTC PINK:MTEHF)(FRANKFURT:M1N) , ("Maxtech" or the "Company") has signed a Letter of Intent ("LOI") to form a joint venture to develop the Buriturama Mine in the State of Bahia, Brazil with Plantiminas Empreendimentos Rurais Ltda.
The Buriturama Mine is located in the northern portion of the State of Bahia, 862 km from Porto de Aratu with access to railroad, port facilities and infrastructure. The intent of the joint venture is to put the asset into commercial production up to 10,000 tonnes per month with focus on the export market.
The project has significant historical mining records as well as a current Gia (trial mining license) which authorizes mining and processing of up to 6,000 metric tonnes of manganese mineralization. Small scale mining has been undertaken on the project and there are manganese outcrops located throughout the project area as well as mining pits. An application has been submitted to Departmento Nacional de Proucao Mineral ("DNPM") for a Lavra licence which provides for unlimited mining. The company will do both technical and legal due diligence on the asset prior to signing a definitive agreement.
Approximately 100km's north of the Buriturama Mine in Bahia is Vale's Mina do Azul Mine, which is responsible for 80% of Vale's manganese output. Vale SA is the largest manganese producer in Brazil, accounting for roughly 70% of the country's market. Mina do Azul is recognized internationally for the excellent quality of its ore, which contains high concentrations of manganese and a high manganese-iron ratio. Its ore is at least 40% pure manganese which is similar in grade to the Buriturama Mines historical records which are not National Instrument 43-101 compliant but which the company believes to be reliable.
The markets for manganese ore and ferroalloys are highly competitive. High-grade manganese ore competes on a global seaborne basis while low-grade ore competes on a regional basis. The ferroalloy market is characterized by a large number of participants who compete primarily on the basis of price. The competitive factors affecting this market are the costs of manganese ore, electricity, logistics, and reductants.
Peter Wilson, Maxtech CEO, said, "We will begin the due diligence process immediately. The Plantiminas Empreendimentos Rurais Ltda. strategic partnership in the Buriturama Mine will enable Maxtech to build vertical manganese operation in Brazil."
The Company also announces that pursuant to its stock option plan it will issue 1,000,000 options to certain officers, directors and consultants at a price of $0.57 cents per share. The options granted are exercisable up to five years from the issue date.
About Maxtech Ventures Inc.
Maxtech Ventures Inc. is a Canadian based diversified industries corporation with gold and manganese mineral properties. Its focus is on mining and the products that are derived therefrom.
For additional information see the Company's web site at http://www.maxtech-ventures.com.
Further information about the Company is available on www.SEDAR.com under the Company's profile.
Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Maxtech Ventures Inc.
Peter Wilson
Chief Executive Officer
604-484-8989
peter@maxtech-ventures.com
info@maxtech-ventures.com
www.maxtech-ventures.com
Maxtech Ventures starts exploration program in Brazil
2017-03-03 04:31 PT - News Release
Mr. Peter Wilson reports
MAXTECH INITIATES PHASE I MANGANESE EXPLORATION PROGRAM IN BRAZIL
John Harper, BSc, PGeo, will be supervising Maxtech Ventures Inc.'s regional exploration programs.
Peter Wilson, chief executive officer, said: "The market for manganese is threefold, in fertilizer it is an essential nutrient in photo synthesis creating greener crops, for steel production in the creation of alloys and of course in high-grade form it is becoming more prevalent in the battery market. Maxtech is well positioned to increase its license holdings as it conducts these regional exploration programs."
Prospecting and mapping, combined with systematic geochemical soil surveys and ground-based geophysical surveys, will be performed to identify and develop manganese mineralization and its trends. There are two styles of manganese mineralization and each method requires different techniques to explore and develop the resource. Mineralization occurs as local cobbles and clasts within the colluvium and saprolite horizons above weathered hydrothermal pyrolusite-bearing veins and the hydrothermal veins themselves.
The current exploration program is designed to test the character and expand the size of colluvium showings that have been identified on the property. Close control for the dimensions and grade will be accomplished utilizing techniques including hand-dug pits, mobile auger drills and trenching with backhoes.
Maxtech's green field exploration strategy for areas with extensive forest cover will be inexpensive, quick and effective while having the least surface disturbance of any exploration method. The hydrothermal vein mineralization is hosted beneath the surficial, weathered horizons. Development of these showings will require further geophysical surveys, both ground and airborne based. Follow-up by traditional core drilling is expected as exploration advances. The technical information contained in this news release has been reviewed and approved by Mr. Harper, who is a qualified person with respect to Maxtech's manganese project as defined under National Instrument 43-101.
The company also announces that pursuant to the company's stock option plan, it is issuing 1.5 million incentive stock options at an exercise price of 47 cents per share to certain officers, directors and consultants. In accordance with the company's stock option plan, the options granted are exercisable for up to five years from the issue date.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
Kootenay Zinc's OTCQB trading shares now DTC eligible
Kootenay Zinc Corp (C:ZNK)
Shares Issued 22,064,294
Last Close 3/9/2017 $0.45
Friday March 10 2017 - News Release
Mr. David Schmidt reports
KOOTENAY ZINC CORP. ANNOUNCES DTC ELIGIBILITY OF ITS OTCQB-LISTED COMMON SHARES & FRANKFURT LISTING
Kootenay Zinc Corp.'s common shares trade on the OTCQB, a U.S. interdealer quotation system, under the symbol KTNNF. The Company's common shares will also continue to trade on the Canadian Securities Exchange under its trading symbol "ZNK". In connection with the OTCQB listing, the Company obtained DTC eligibility with the Depository Trust Company for its common shares on the OTCQB. The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corp. and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered DTC eligible. This electronic method of clearing securities speeds up the receipt of shares and cash, and thus generally accelerates the settlement process for investors.
Achieving DTC eligibility to simplify trading of the Company's common shares on the OTCQB market makes it accessible to an even broader range of investors and is expected to assist with the Company's goal of increasing the liquidity and convenience of trading its common shares within the U.S.
In addition, the Company announces that its common shares trade on the Frankfurt Stock Exchange under the symbol "KYH" which should help increase the Company's shareholder base and provide increased access to the European capital markets.
About the Company
Kootenay Zinc Corp. is a mineral exploration and development company based in Vancouver, British Columbia that is presently targeting the Sully Property. The Company is focused on discovering large-scale sedimentary-exhalative ("SEDEX") deposits.
The Sully Property comprises 1,375 hectares located approximately 30 kilometres east of Kimberley, B.C., and overlies rocks of similar age and origin as those which host the world-class Sullivan deposit, owned by Teck Resources Ltd. Sullivan was discovered in 1892, and is known to be one of the largest SEDEX deposits in the world. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately three hundred million ounces of silver, eight million tonnes of zinc and eight million tonnes of lead. The equivalent level of strata as at Sullivan and that formed on the margin of that same basin are present at the Sully Property. The Company cautions that past results or discoveries on proximate land are not necessarily indicative of the results that may be achieved on the Sully Property.
The scientific and technical information contained in this news release has been reviewed and approved by the Company's Project Manager, Paul Ransom, P.Geo., a "Qualified Person" as defined in National Instrument 43-101 - Standards of Disclosure for Mineral Projects.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd.
Here is an informative 3D Signatures Inc. video clip
http://bit.ly/2n2VvFQ
http://www.3dsignatures.com/wp-content/uploads/2017/03/3dtt_3ds001_animation_en_1080p_high.webm
3D's TeloView can predict cancer stability, says study
3D Signatures Inc (C:DXD)OTC-TDSGF
Shares Issued 46,445,199
Last Close 2/21/2017 $0.88 CDN $.67 USA
Tuesday February 21 2017 - News Release
Mr. Jason Flowerday reports
3D SIGNATURES TO PRESENT POSITIVE RESULTS FOR PROSTATE CANCER LIQUID BIOPSY
Later today Dr. Sabine Mai, 3D Signatures Inc. co-founder and principal inventor, will present the results of a prospective blood-based prostate cancer pilot study using the company's proprietary TeloView software platform. The results will be presented at the 24th International Molecular Medicine Tri-Conference in San Francisco, CA. Based on blinded blood samples, TeloView correctly predicted the stability and aggressiveness of disease for each of the study's 50 intermediate risk prostate cancer patients.
A prospective prostate cancer patient cohort was assessed to evaluate TeloViewTM's potential to blindly stratify 50 intermediate risk prostate cancer patients (Gleason 7, PSA <20) and monitor their disease progression or stability. Patients were recruited after informed consent, blood was drawn and circulating tumor cells ("CTCs") were isolated prior to radical prostatectomy. CTCs were isolated from blood samples from each of the 50 patients.1 Surgery results correlated with the observed three-dimensional nuclear telomeric profiles from CTCs and indicated that the TeloView platform correctly identified each patient with stable vs. progressive disease (p=0.0175).
"These results are extremely encouraging," stated Jason Flowerday, CEO of 3DS. "We believe that the TeloViewTM software platform is a disruptive technology. It is based on a universal structural biomarker, 3D telomere organization, that has generated impressive results across a number of diseases, with prostate cancer being one of our highest priorities." In previous clinical research, TeloViewTM has also demonstrated the ability to identify and profile multiple CTC clones within a single patient (heterogeneity)1,2 as well as the ability to monitor and quantify changes to 3D telomere profiles as a result of treatment (before and after).3 Based on clinical data produced by Dr. Mai and her colleagues, 3DS believes that TeloViewTM is a promising candidate for development as an accurate, blood-based risk-assessment and monitoring platform for prostate cancer. As announced on October 19, 2016, TeleViewTM will be included in a multicenter Canada-wide prostate cancer clinical trial, known as PRECISE, to identify and monitor prostate cancer patients suitable for active surveillance.
About 3DS
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
1 Adebayo Awe J, Saranchuk J, Drachenberg D, Mai S. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. Urol Oncol. 2017 Feb 12. pii: S1078-1439 (16) 30415.
2 Awe JA, Xu MC, Wechsler J, Benali-Furet N, Cayre YE, Saranchuk J, Drachenberg D, Mai S. 3D telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations. Translational Oncology. 2013 2013 Feb; 6(1):51-65.
3 Wark L, Thomas Klonisch T, Quon H, Mai S. Three dimensional telomere signature dynamics in circulating tumor cells of early follow-up high-risk prostate cancer patients undergoing androgen-deprivation and radiation therapy. Urol Oncol. 2016 Dec 9. pii: S1078-1439 (16) 30332-5.
© 2017 Canjex Publishing Ltd.
Proven Advisory and Geological Team
In accessing the risk reward aspect of the Kootenay Zinc and value of it's stock its important to note the strength of the Advisory Board and Geological personal.
The Kootenay Zinc team has been directly associated with world class discoveries that were then sold of billions of $$.
The geological team is outstanding with a track record of working on mega mining projects including the Sullivan and Voisey Bay.
Reference the Kootenay Zinc Web site for career highlights of these talented individuals.
http://www.kootenayzinc.com/mgmt
http://bit.ly/2kJVk3y
Canadian Mines & Energy profiles Kootenay Zinc Corp
Mining and Exploration logo
Home General Could there be another Sullivan mine-sized depo
Could there be another Sullivan mine-sized deposit near Fort Steele, B.C.?
Fort Steele may have a new neighbour soon: The Sully mine
by Kyle Born
Paul Ransom points to Lakit Lookout, near Fort Steele, which could be the next big East Kootenay mine.
The East Kootenay rumour mill has swirled for years about a new mine opening to rival the old Sullivan mine. Thus far, nothing has materialized. But perhaps that’s about to change.
This potential new mine is Sully, located five kilometres northeast of Fort Steele at the base of Lakit Mountain. Dr. David Broughton, senior technical advisor for Kootenay Zinc Corp., based in Vancouver, said, "The coincidence of multiple large gravity anomalies with strata of Sullivan-equivalent time makes the Sully project very compelling. The project team appears to be closing in on discovering the source of the gravity anomalies."
Heading that team is Paul Ransom, a longtime Kootenay resident and geologist for Kootenay Zinc Corp. He is hopeful that this deposit will be the big one that has eluded prospectors over the years.
“We should be very optimistic,” he said, although he cautioned, “Proof of concept and nature of any mineralization are needed before making odds of going into production. Geological mapping is a giant puzzle-solving process. It’s the ultimate treasure hunt.”
If anyone has an edge at finding the motherlode, it’s Ransom. He used to work at Sullivan, mapping underground workings from ore outline drilling. He progressed to surface exploration mapping and drilling near the mine and occasionally returned to the mine to work on special research projects.
At this stage, Sully is an exploration project. Because of the metal it contains, an ore deposit such as Sullivan is about twice as dense as the rock surrounding it. Gravity surveying, a geophysical technique that detects changes in density of the Earth's crust, indicates there is a dense mass at Sully that could be explained by the presence of a large orebody. Proof of concept by drilling is required.
Kootenay Zinc will be commencing drilling as soon as permits are received and a drill can be mobilized to the site, which is likely underway by February.
Discovery of lead and zinc mineralization is expected but this needs to be confirmed. Continuity of mineralization needs to be established and the size of deposit determined. It would likely take two years to make an initial evaluation following discovery.
Ransom sees the East Kootenay as an ideal location for a mine. “It has well-developed infrastructure including a rail line to a smelter in Trail, B.C.,” he said. “Communities nearby have many experienced miners who work away and would prefer to work close to home.”
The positive economic impact the Sully mine would have on the East Kootenay would be large. Businesses would see increased volumes from the expansion as mining professionals and support service individuals would need places to live and spend their money.
“Mineral deposits that can be mined put phenomenal wealth into circulation and are important for community development,” said Ransom. “If such is discovered at Sully, this region will prosper and there will be employment opportunities for several decades.”
www.kootenayzinc.com
CSE/ZNK
A Zinc Opportunity...
Dear Alphastox Subscribers,
I’ve been getting a ton of inquiries over the last week since our last article on our next Zinc play to watch so I decided to feature the name a little earlier than expected. It’s a company I became a shareholder in and absolutely love their prospects. The ONE Zinc company that I feel has the potential to have an amazing run in 2017 is Kootenay Zinc Corp. (CSE:ZNK). This is a good of a shot as anything I’ve seen , and with the mining market picking up over the last little while, this is one company you can’t afford to miss.
Kootenay Zinc is now fully funded after closing an over-subscribed $3.3 million financing and is perfectly positioned to generate substantial shareholder value. The capital was raised to drill the company’s Sully Project, located just 30km away from the legendary Sullivan mine (owned and operated by Teck Resources and produced over 17 million tonnes of lead and zinc and 337 million ounces of silver from 150 million tonnes of feed. At current prices value of production was US $49 Billion). The Sullivan mine was a Sedex deposit, and what attracted me most to the project was the fact that ZNK’s team see similarities between the two projects.
According to ZNK’s website: “The same stratigraphic level that Sullivan was deposited at appears to coincide with the East gravity anomaly at Sully. A subtle lead-zinc soil anomaly possibly reflects leakage up faults and dispersion through thick till and alluvium from an entirely buried deposit.”
Initial surveying by the team indicated a shallow mass that was missed by drilling in 2004. In 2014, downhole temperature and magnetic field readings indicated the target may have been missed by 100m and new gravity data conducted by ZNK confirm and better define the location of a large East mass. With this new information, management intends to undertake a drill program to target this east mass which could be huge and lead us to the mother load…
Now, obviously after reading all this and going through the company’s website for more information on the project (which I highly encourage everyone to do here: http://www.kootenayzinc.com/), one couldn’t help but put ZNK on their radar screen and potentially take a shot at something that could become the next Sullivan mine, but what’s even more striking for this ~ $24 million market cap
exploration play is the team they have leading the charge; it’s the “Who’s Who of the mining industry.”
Don’t believe me? Take a look at their bio’s below and judge for yourself:
Peter Meredith
Mr. Meredith has been a director of Ivanhoe Mines Ltd. (formerly, Ivanplats Limited) since May, 1998. Mr. Meredith is the former Deputy Chairman and Chief Financial Officer of Ivanhoe Mines Ltd. (now Turquoise Hill Resources Ltd.), where he was involved in overseeing Ivanhoe Mines Ltd.’s business development and corporate relations. Mr. Meredith was member of the board of directors of Ivanhoe Mines Ltd. and also served as its Chief Financial Officer from June, 1999, to November, 2001 and from May, 2004, to May, 2006, and as its Deputy Chairman from May 2006 to April 2012. Mr. Meredith was also Chairman of South Gobi Resources Ltd. until September, 2012.
Jonathan Rubenstein
Mr. Rubenstein is the chairman of Mag Silver Corp., a director of Detour Gold Corp. and a director of Eldorado Gold Corp. He is also Vice President, Corporate Secretary and a Director of Andagan Resource Corp. In 2001, Mr. Rubenstein was one of the founders of Canico Resources Corp., where he served as a Director, Vice President & Corporate Secretary as the company acquired, explored and developed its Onc¸a Puma nickel deposit in Brazil. Mr. Rubenstein was instrumental in the negotiations for the 2005 acquisition of Canico by CVRD of Brazil for $941 million. As vice president, corporate affairs for Sutton Resources, he also played a key role in negotiating the $525 million takeover of that company by Barrick Gold Corp. in 1999.
Tookie Angus
Mr. Angus is an independent business advisor to the mining industry. Mr. Angus is the former chairman of the board of B.C. Sugar Refinery Ltd. He was a director of First Quantum Minerals until June, 2005, a director of Canico Resources Corp. until its takeover by CVRD in 2005, and a director of Bema Gold until its takeover by Kinross Gold in 2007. More recently, he was managing director of mergers and acquisitions for Endeavour Financial, a director of Ventana Gold until its takeover by AUX Canada Acquisition in 2011, and a director of Plutonic Power until its merger with Magma Energy in 2011. He is currently chairman of Nevsun Resources Ltd., which operates one of the highest-grade open-pit copper mines in the world. He is also the curent chairman of K92 Mining Inc.
PAUL RANSOM (P. GEO)
Mr. Ransom is a geologist and noted Sullivan SEDEX deposit expert, having worked for over 33 years with Cominco, now Teck Resources Limited. Much of his career was spent at Sullivan related to the regional geology. Mr. Ransom has authored and/or co-authored ten papers on geology of the Sullivan deposit. Mr. Ransom also spent 1.5 years as a project geologist under secondment to Mt. Isa Mines in Australia, another large- scale copper, lead, zinc and silver mine. Mr. Ransom managed drilling Sullivan Deeps and has worked extensively elsewhere in the Kootenay region of B.C. He has also worked in the Yukon, NWT, Nunavut, Quebec and Nova Scotia. Mr. Ransom’s passion for finding other mega-SEDEX deposits has been a career-long pursuit.
DR. DAVID BROUGHTON PhD GEO.
Dr. David Broughton joined Ivanhoe Mines in January 2008 and has overseen Ivanhoe Mines’ discovery of two major mineral deposits, Kamoa in the DRC and the Flatreef in South Africa.
Dr. Broughton is recognized as an expert in sediment-hosted copper deposits, and has been a key participant in several discoveries and successful development projects. (DRC), Namibia, China, United States, Canada and Poland. He was co-leader of the Kamoa discovery team that is the 2015 recipient of the Prospectors & Developers Association of Canada’s (PDAC) prestigious Thayer Lindsley Award. This award, honouring the memory of one of Canada’s greatest mine finders, recognizes an individual or a team of explorationists credited with a recent significant mineral discovery.
BRIAN JONES P.GEOPHYS
Mr. Jones and Excel Geophysics are noted gravity experts and consultants, having completed notable large-scale surveys for mineral exploration and resource estimates, including the Voisey’s Bay Project. Inco Ltd. purchased Diamond Fields Resources Ltd. which owned the Voisey’s Bay Project for $4.3 billion.
I have yet to find a company with a similar market cap with a better team than this one…when I first looked at their roster, I pulled out my cheque book in an instant and begged for the subscription agreement. These guys have generated billions in shareholder value over the last decade, taking tiny exploration companies and turning them into mid-tier producers. There isn’t a better team qualified to find and develop early stage projects than this one and I can’t wait to see what they can do here.
Someone asked me a few days ago “why would these mining tycoons bother getting involved with a small exploration company like ZNK when they’re busy running billion dollar deposits?” The answer is simple: they want to put their name all over another massive discovery and they obviously felt like ZNK’s Sully Project had that chance. Make no mistake, they didn’t need to get involved with ZNK, or any company for that matter, but they did, because of the opportunity they saw. It’s obviously a long shot, and at the end of the day, our fate lies in the drill bit, but if they hit, early speculative investors with a high enough risk tolerance will be heavily rewarded.
The team is just starting to get the word out before they start their drill program. I am long the stock and will continue to provide coverage for subscribers throughout their drill campaign so stay tuned. This is a name you don’t want to miss.
Disclosure: Transcend Capital Inc. is a shareholder of Kootenay Zinc and has been paid a fee
Disclaimer
The information and recommendations made available here (“Information”) by Alphastox.com and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Transcend Capital Inc. nor Alphastox.com will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.
Alphastox.com nor Transcend Capital Inc. is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgement in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.
In no event will Alphastox.com be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.
This is not an investment advisory, and should not be used to make investment decisions. Information on Alphastox.com and though its letter is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of Alphastox.com may have positions in the stocks discussed above and may trade in the stocks mentioned. Don’t consider buying or selling any stock without conducting your own due diligence.
3D Signatures A New Class of Biomarkers
http://www.equedia.com/3d-signatures-new-class-of-biomarkers/
3D Signatures: An Entirely New Class of Biomarkers
EQUEDIA NOVEMBER 6, 2016 19.7K 6
I wrote a check for $50,000 into this Company.
That’s because I believe that this $50,000 could soon be worth many times that.
In fact, in just a bit, I’ll show you why a 15,700% potential return is possible from here.
And it all starts with a very special situation that could soon propel the shares of this Company.
It’s one that involves one of the smartest scientists in North America and her breakthrough in a multi-billion dollar, life-changing industry.
It’s why she was named one of the most powerful women last year.
Yet, very few investors know about this Company – but I believe very strongly that many soon will.
This isn’t just a random breakthrough.
This Company has over 20 years of research, more than $25 million spent on R&D, and patents in both N. America and Europe for its breakthrough discovery.
This technology is a first-of-its-kind and has the potential to change an industry worth billions upon billions of dollars.
And it’s about to transition from the lab to the real world.
That could mean serious profits for a company with a market cap of barely over CDN$30 million – incredible considering the amount of research and money already poured into this technology.
It also means shareholders could soon be rewarded as well.
It’s no wonder why big names are already jumping at the chance to get involved.
In fact, one big pharmaceutical company just invested $1 million into this tiny junior and has already signed an exclusive license and distribution agreement to lock down this tech in certain parts of the world.
But big profits are just a small benefit to what this Company could soon achieve.
This Company has the potential to change lives.
Serious as Cancer
Chances are you or someone you know is going to get cancer.
I don’t mean to sound harsh, but 40% of us will be diagnosed with cancer at some point during our life.
In the U.S. alone, The National Cancer Institute estimates that about 595,690 Americans will die of cancer this year. That’s more than one every minute.
But this should come as no surprise.
I am sure many of you have already gone through a very difficult time in dealing with cancer – whether it was your own or someone you love.
I know I did.
A Most Difficult Decision
That brings me to a very difficult subject.
Anyone who has had to deal with cancer knows that one of the most difficult decisions we can make is how we deal with it.
That’s because after a cancer diagnosis, patients and their families have to make a number of decisions about treatment.
How do we know what treatment is right?
Do we need radiation?
Do we need surgery?
Do we need chemotherapy?
How do we know if one treatment is better than another?
How do we know if a treatment is actually working?
There isn’t a simple answer for any of these questions because there is no “one size fits all” treatment for any cancer.
Unfortunately, that means many diagnosed with cancer are often mistreated, or worse, over-treated.
According to the Prostate Cancer Foundation:
“…current estimates indicate that 30% more men are aggressively treated for prostate cancer than is necessary to save a life from the disease.”
This not only costs healthcare payers billions of dollars every year, but it often inflicts unnecessary treatment and complications on patients.
For example, chemotherapy and radiation are often used to fight cancer – both of which can take a serious toll on a patient.
Here is just one story of a women named Hazel…
Via Cancer Tutor:
“Two years ago, Hazel was diagnosed with breast cancer. She described her chemotherapy as the worst experience of her life.
“This highly toxic fluid was being injected into my veins. The nurse administering it was wearing protective gloves because it would burn her skin if just a tiny drip came into contact with it. I couldn’t help asking myself, ‘If such precautions are needed to be taken on the outside, what is it doing to me on the inside?’
“From 7 p.m. that evening, I vomited solidly for two and a half days. During my treatment, I lost my hair by the handful, I lost my appetite, my skin color, my zest for life. I was death on legs.”
She is not alone in her experience. Nearly everyone who undergoes such harsh treatments has similar stories.
Now imagine if it turned out that after the chemotherapy, her cancer didn’t die.
Imagine if we later found out that another treatment would have been the better option?
That’s just the tip of the iceberg:
“…Some 67 percent of people who die during cancer treatment do so through opportunistic infections arising as a direct result of the immune system failing because of the aggressive and toxic nature of the drugs.”
In other words, some cancer treatments can even lead to death.
Yet, despite all of this, there hasn’t been an accurate way to tell what treatment is best for those diagnosed with cancer. Nor have there been ways to determine how a patient is reacting to treatment in real time.
That’s why one of the biggest challenges for cancer physicians is recommending the right treatment.
No physician wants to be responsible for mistreating a patient.
But what if it didn’t have to be this way?
What if there was a technology that could more accurately inform you about treatment?
What if there was a technology that could not only determine how your disease is progressing, but also how you’re responding to treatment in real time?
Why go through the perils of radiation, chemotherapy, or surgery if it might not work?
Anyone who has ever had to deal with cancer knows just how significant this could be.
After 20 plus years of research, more than $20 million in R&D, more than 100 peer-reviewed papers, and 16 clinical studies, one of 2015’s most powerful Canadian woman is about to bring such a technology to the world.
Her name is Dr. Sabine Mai and her breakthrough research is finally moving from the bench to the bedside to enable better treatment and monitoring options for patients.
That’s why she co-founded the company I am about to introduce.
And that’s why the value of this Company could soon soar.
3D Signatures Inc.
Canadian Trading Symbol: TSX-V: DXD
US Trading Symbol: OTCQB: TDSGF
German Trading Symbol: FSE: 3D0
An Entirely New Class of Biomarkers
3D Signatures Inc. (3DS) has discovered an entirely new class of biomarkers for diagnosis, assessment, and monitoring of major diseases, with a current focus on Cancer and Alzheimer’s Disease.
The discovery of a new biomarker alone represents a major breakthrough.
A biomarker is “a measurable substance in an organism whose presence is indicative of some phenomenon such as disease, infection, or environmental exposure.”
According to a new report by Grand View Research Inc., the global biomarkers market is expected to reach over US$78.2 billion by 2024.
And according to market research firm Kalorama, the cancer biomarker is expected to reach over US$7.4 billion by 2020.
But 3DS has gone far beyond just identifying a new biomarker.
Using this new biomarker, 3DS has developed precision clinical tests that are powered by a proprietary software platform that can measure:
the stage of disease
the rate of progression of a disease
drug efficacy
and drug toxicity
That means instead of “guessing” what treatment to use based on “guessing” the stage of disease and “guessing” how it’s progressing, we no longer have to “guess.”
It potentially means once we select a treatment, we can know right away if it’s working, see if there are any adverse side effects, and know if the treatment is doing more harm than good – all in near real-time.
In fact, the technology is designed to predict the course of a disease and customize treatment for each individual patient.
This has never been done before.
All of this is backed by more than 20 years of research and has already been validated in numerous papers, supported by 16 successful clinical studies on over 1,500 patients on 13 different cancers (including prostate, breast, lung and multiple myeloma), and Alzheimer’s disease.
This type of personalized treatment is truly groundbreaking and could soon be adopted by clinics everywhere.
For a company worth just over CDN$30 million, the upside could be tremendous.
I’ll get back to this in a bit.
But before I do, it’s important to understand how it works.
How 3DS Technology Works
Every human has DNA that is packaged into chromosomes.
At the tip of each chromosome are protective regions of DNA called telomeres.
3d-telomeresBy using fluorescent markers and high-resolution microscopes, we can see the location of each telomere within a cell nucleus and digitally analyze it.
3DS patented software platform then analyzes an individual’s three-dimensional chromosomal structure or “Signature” and specifically analyzes the patient’s telomeres in a three-dimensional manner.
This three-dimensional organization of telomeres within a cell nucleus is highly predictive with respect to the health of that individual cell.
In other words, we can tell a lot just by looking at the health and shape of these telomeres.
So how does that help us?
Screening – Who has a particular disease?
Diagnosis – What kind of disease/cancer?
Prognosis – How stable or aggressive is the disease/cancer?
Predicting – How will the patient respond to a particular treatment?
Monitoring – Stability/progress of patient over course of treatment
Drug Development – Identification/development of better drugs
Real-Life Scenario
Depending on the disease, a clinic takes a tissue, blood, or a cheek swab sample.
This sample is then preserved and labeled.
Pictures of these samples are then taken from multiple 3D perspectives, which are then exported to a centralized 3D Signatures analytics centre.
Once at the centre, the images are analyzed and then given a scoring model based on the parameters generated by 3DS technology.
A personalized report is finally generated and sent back to the clinic with clear information for the patient.
It’s a super simple, non-invasive process.
With 3DS, we can now accurately provide a host of predictive medical information in real-time, using nothing more than blood, cheek swab or tissue samples.
The impact and benefits of this technology are truly significant.
Helping medical professionals deliver the best care protocols for each patient will not only benefit patients immensely, but it could save health care providers billions of dollars by reducing ineffective, improper, and unnecessary treatments.
Imagine what it could save for insurance companies.
The potential market for this alone is staggering.
But just how big is the market?
Creating Beachhead
As of right now, 3DS trials include 14 diseases and 16 clinical trials on over 1500 patients.
3ds-current-market-studies
Here is the pipeline and stage of each niche for 3DS technology:
3ds-current-progress
As you can see, 3DS works on a wide spectrum of diseases, with many of them already moving into the development and validation stage. In fact, there is potential to work on even more diseases and cancers.
But for now, let’s focus on the two that are closest to market.
3ds-hodgkins
Hodgkin’s Lymphoma
For almost all patients with Hodgkin disease, cure is the main goal.
The 2 main ways of treating Hodgkin disease are chemotherapy and radiation therapy. Depending on the situation, one or both of these treatments might be used.
However, these treatments can have side effects that often don’t show up for many years. Because of this, doctors try to choose a treatment plan with the lowest risk of possible side effects.
But since physicians can’t predict whether a patient will respond to standard chemotherapy and enter long-term remission or not respond and relapse, treatment choices become even more difficult to make.
It also means that patients have no way of knowing if the treatments are working until long after it’s over.
By that time, the treatments could have done more harm than good.
There simply is no test capable of providing clinicians with the type of information for proper treatment in real-time.
Except for 3D Signature’s platform.
3DS is designed to determine whether an individual will respond to standard chemotherapy almost immediately.
Once a treatment is selected, it can also determine if the treatment is working in real time.
Those who are shown to not respond to chemotherapy can then receive optimized alternative treatments resulting in:
New treatment options
Reduced secondary complications
Significant cost savings
This is truly groundbreaking when it comes to treating those diagnosed with Hodgkin’s Lymphoma.
But as significant as this is, Hodgkin’s Lymphoma is a small market when compared to other cancers.
Such as prostate cancer…
3ds-prostateProstate Cancer
One in seven men will be diagnosed with prostate cancer during his lifetime.
And one in 39 men will die from it.
In fact, there are over three million existing and new cases of prostate cancer in the United States and Canada alone.
As I mentioned earlier, many diagnosed with prostate cancer are often mistreated because of the dangers that might arise if left untreated.
If we could avoid over-treating the 80% of men with low-grade disease who will never die of prostate cancer, we would save billions of dollars every year.
More importantly, thousands of men may not have to suffer some of the dangerous treatments involved in treating prostate cancer.
Right now, there is no test to accurately determine which intermediate-risk patients will progress to an advanced cancer and require immediate aggressive treatment.
But 3DS technology is designed to stratify patients into several risk categories and predict the most effective treatment plan.
And best of all, the test is a non-invasive risk assessment and monitoring platform based on a blood sample, and not a prostate biopsy.
US$9 Billion-Dollar Prostate Cancer Market
Based on an estimated retail price of US$3,000 per 3DS Telo-PC test, the total market revenue could be over US$9 billion per year!
Let’s put that into perspective.
If 3DS captures just 10% of the prostate test market, that’s nearly US$1 billion in revenue.
3DS is worth barely over CDN$30 million as I write this.
The average price to sales ratio of those in the healthcare information and technology space is 3.54.
Using back-of-the-napkin math, based on the 3.54 ratio, the current US-CDN exchange rate of 1.34, current 3DS share structure, and assuming 3DS captures 10% of the prostate test market, it means 3DS could be worth over CDN$96 per share!
That’s a potential return of more than 15,700%!
3ds-prostate-test-market-sizeOf course, take the back-of-the-napkin calculation with a grain of salt.
It will take time for 3DS Telo-PC to fully come to market and there are other risks along the way. The Company will likely dilute further as they raise more money to progress, and going to market involves time and risks.
I am also not saying that once 3DS technology comes to market in full for prostate cancer that everyone will take the test, nor will it be fully adopted by every clinic – that would be very optimistic thinking.
prostate-biopsyBut if you’re a man reading this, would you rather take a non-invasion blood sample or a very invasive prostate biopsy?
I wouldn’t think twice about which one I prefer.
And while there are other tests one can do for prostate cancer, 3DS is a dynamic biomarker that can be used throughout the course of the disease and treatment(s).
All of the other tests are static, meaning each test is only relevant for a particular piece of information/stage.
But that’s not all.
3ds-prostate-competitorsAll of the other tests are statistically based, meaning they will provide a probability of progressing within a period of time.
In other words, the other tests are practically a guessing game.
3DS, on the other hand, is a real-time assessment of what stage you’re at and what treatment you need the day you take the test.
It’s a one test fits all.
Lastly, all of the other tests are focused on “the cancer” versus the capacity of dealing with tumour heterogeneity.
Essentially, if you have prostate cancer, you have more than one type of cancer within that tumour.
3DS looks at many circulating tumour cells and can identify and assess multiple tumour subpopulations with the same test.
The implications are significant with respect to understanding the disease and appropriate treatment.
In short, there simply is nothing like 3DS.
That’s precisely why just last week, 3D Signatures Inc. announced that it was one of the few invited to participate in the first randomized, multicenter study focused on biopsy naive patients with clinical suspicion of prostate cancer, known as PRECISE.
3DS Included in One of the Most Significant Clinical Studies in North America for Prostate Cancer
Even more important is what Principal Investigator, Dr. Laurence Klotz, the Chairman of the Canadian Urology Research Consortium and a renowned uro-oncologist and prostate cancer thought leader had to say about 3DS:
“We have an opportunity to test a new blood-based biomarker to accurately stratify patients into risk groups. If successful, this could represent a first-in-class blood test, which would specifically identify clinically significant prostate cancer. Such a tool does not currently exist for prostate cancer patients.”
SUCH A TOOL DOES NOT CURRENTLY EXIST FOR PROSTATE CANCER PATIENTS.
It’s no wonder why 3DS involvement in this study is being funded by the Ontario Institute for Cancer Research and the Movember Foundation Canada:
“Awarded by way of a rigorous peer review process run by Prostate Cancer Canada, this multimillion dollar project is funded by the Ontario Institute for Cancer Research (OICR) and the Movember Foundation Canada. To support its participation in PRECISE and the development of related clinical tests, 3DS’ projected budget is approximately $2.4M over a two-year period which represents at least 50% savings over an independently run study.”
First to Dollar, Then to Regulator
Now here’s the kicker: unlike a drug treatment, 3DS doesn’t have to go through all of the hurdles before it can make money.
It can begin to have clinics using the technology long before full validation of each individual disease – and that means it can begin making money almost immediately.
The best part is that 3DS is just at the beginning stages of roll out to the medical community, which means this is ground-floor investing for a platform that could completely change the way diseases are diagnosed and treated.
But that’s just the tip of the iceberg.
Aside from just clinical tests for patients, which could lead to saving billions of dollars and thousands of lives, there could be something even bigger.
And I am not talking about the billions of dollars in potential revenue for the tests.
In fact, it’s so big and unique that I am not sure how to value it just yet. But I am betting Big Pharma might have an idea.
Let me explain.
Drug Development
Drug development is one of the most costly, time-consuming, and riskiest businesses in the world.
According to a report published by the Tufts Center for the Study of Drug Development (CSDD) back in 2014, the cost of developing a prescription drug that gains market approval is a whopping US$2.6 billion.
Source: Tufts Center for the Study of Drug Development via Scientific American
Source: Tufts Center for the Study of Drug Development via Scientific American
Add in post-approval development – studies to test new indications, formulations, and dosage strengths – and costs spike up to nearly US$3 billion.
And, as you can see, the costs have been exponentially rising, year after year.
More importantly, the costs of clinical trials have not only surpassed the costs of preclinical trials but is becoming increasingly more expensive.
That’s because, on average, it takes over a decade to bring a new drug to market.
According to Medicine Net:
“In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to your medicine cabinet. That is if it makes it.
Only 5 in 5,000 drugs that enter preclinical testing progress to human testing.
One of these 5 drugs that are tested in people is approved.
The chance for a new drug to actually make it to market is thus only 1 in 5,000.”
So not only is it expensive, it’s extremely time-consuming and extremely risky.
But what if we could shorten this time during the most expensive part of the drug approval, the clinical trial?
You see, a lot of the time spent on the drug approval process is during clinical trials – which is one of the reasons it costs a lot of money.
Clinical trials have many phases, starting with a small group of patients and then more and more as we move through the phases.
During each phase, volunteer patients are monitored to see how they react to the drug.
In other words, wait and see.
But what if drug companies didn’t have to wait and see?
What if they could know in real-time if the drug was working?
What if they could know in real-time if the drug was toxic?
What if they could know in real-time how certain drugs reacted with different individuals?
That’s precisely what 3DS could soon do for Big Pharma.
Based on published work by Dr. Mai and her collaborators regarding real-time ex-vivo feedback on several new therapeutic candidates and inbound interest from a number of major pharmaceutical companies, 3D Signatures is already in discussions around partnership opportunities with some very big names.
That’s because 3DS technology has the potential to identify lead therapeutic candidates through drug-screening, select specific patients for clinical trials, monitor patients during clinical trials, and ultimately work with pharmaceutical companies on the approval of companion diagnostics for precision medicine.
There is significant potential value to be realized by pharmaceuticals companies in the form of efficient identification of new drugs, targeted clinical trials, objective real-time feedback during clinical trials, and expedited regulatory approval by way of companion diagnostics.
Which is precisely why 3DS is focusing on already approved products and late-stage drug trials to commercialize companion diagnostics.
In fact, as I just mentioned, discussions are already underway with several major pharmaceutical companies.
Don’t be surprised to see 3DS announce a major partnership with a big-name pharma company in the near future.
The potential for what 3DS real-time ex-vivo feedback can do for both patients and Big Pharma is massive.
It’s precisely why the Company has attracted some of the top minds in the industry.
I could write a full report on the list of who’s who involved in 3DS, but here’s a brief example of the credentials from the management, board, and advisors – together, they combine decades of experience in diagnostics, healthcare, pharmaceutical and business.
Business development and marketing work at some of the world’s largest pharmaceutical companies, including Germany’s Bayer AG and US-based Johnson and Johnson.
Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba. Internationally known researcher with more than one hundred publications related to research on Genomics and Genomic Instability. Recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013).
Chairman of the Centre for Imaging Technology Commercialization. Former Director General of the NRC Institute for Biological Sciences, Ottawa, ON, and founder and Director General of the Institute for Biodiagnostics, Winnipeg, MB. 2008 Outstanding Achievement Award of the Public Service of Canada. Awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for contributions.
Internationally recognized for contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance as a standard aspect of patient care. Widely published uro-oncologist and a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Awarded the Order of Canada in 2016 for his contribution to prostate cancer treatment.
How about business advisor Jonathan Goodman, Director & CEO of Knight Therapeutics Inc., who just put CDN$1 million into 3DS?
Then there’s advisor Dr. Heiner Dreismann who is Past President and CEO of Roche Molecular Diagnostics.
I could go on but you get the point. If you want to learn more about the 3DS team, I’ve included it at the bottom of this Letter.
The people backing 3DS is why I believe in this Company, its platform, the science behind it, and the upside it could provide for early shareholders.
Near-Term Catalysts
As you can imagine, such a profound new technology and research has not gone unnoticed by industry experts – even if its under the radar of financial institutions.
As hinted by 3DS, a steady stream of positive news flow is expected including talent acquisition, clinical trial progress, and new business developments.
All of this means that we could witness some big announcements as early as next year that could significantly propel the Company to new heights.
I confidently believe that once the 3DS business strategy rolls out, institutions will want a piece of the pie.
Conclusion
Based on Dr. Sabine Mai’s groundbreaking research, 3D Signatures is the first and only company to understand and quantify normal versus disease state telomere arrangement, turning this into usable, predictable, reliable, and highly valuable information that can improve patient outcomes.
Highly promising and unconventional software platform is already attracting attention from multinational healthcare companies relatively early in the product development process.
What 3DS is doing is truly remarkable.
We rarely see this type of talent, bandwidth, and opportunity in a junior with such a small market cap.
That’s because few people really know about 3DS. The management team aren’t promoters – they’re business operators and science professionals with incredibly deep backgrounds and a track record of success.
They’re doctors who other doctors ask for advice.
This may be a small company now with a small retail investment market, but I don’t expect it to be for long.
Which means the window of opportunity is closing for early investors.
3DS is right on the brink of not only numerous milestones, but it could also soon begin to generate revenue.
It’s why I invested in this Company and why I think many smart people will too.
3D Signatures Inc.
Canadian Trading Symbol: TSX-V: DXD
US Trading Symbol: OTCQB: TDSGF
German Trading Symbol: FSE: 3D0
Seek the truth,
Ivan Lo
The Equedia Letter
www.equedia.com
Disclosure: We’re biased towards 3D Signatures Inc. because the Company is an advertiser. We currently own shares purchased in a private placement. You can do the math. Our reputation is built upon the companies we feature. That is why we invest in every company we feature in our Equedia Special Report Editions, including 3D Signatures Inc. It’s your money to invest and we don’t share in your profits or your losses, so please take responsibility for doing your own due diligence. Remember, past performance is not indicative of future performance. Just because many of the companies in our previous Equedia Reports have done well, doesn’t mean they all will. Furthermore, 3D Signatures Inc. and its management have no control over our editorial content and any opinions expressed are those of our own. We’re not obligated to write a report on any of our advertisers and we’re not obligated to talk about them just because they advertise with us.
3ds-captial-structure
3DS Board, Management, and Advisors
JOHN SWIFT, LLB, CHAIR, BOARD OF DIRECTORS
Past Principal Secretary in the Prime Minister’s Office and Chief of Staff, Office of the Leader of the Opposition, Government of Canada. Past board member of GenXys Health Care Systems, Inex Pharma, Ultrasonix Medical Corp. and Neuromed Technologies Inc. Past Chairman of Central City Foundation.
JASON FLOWERDAY, CEO & DIRECTOR
Mr. Flowerday has extensive life sciences leadership experience including over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson. Other notable positions include executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio Inc. Mr. Flowerday was also co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications. He is an independent Director of Aequus Pharmaceutical
SABINE MAI, PHD, DIRECTOR AND CHAIR, CLINICAL AND SCIENTIFIC ADVISORY BOARD
Dr. Sabine Mai is currently Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba. She is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
FERENC SOMOGYVARI, DIRECTOR
Co-founder and former GM of Carl Zeiss Microscopy with more than 38 years in the optical medical and biology industries. Former CEO of 3D Signatures.
IAN SMITH, PHD, DIRECTOR
Dr. Smith, OC, PhD, DSc, FRSC, is currently the Chairman of the Centre for Imaging Technology Commercialization. His past research and commercialization achievements include significant success in the field of magnetic resonance imaging. Dr. Smith is a former Director General of the NRC Institute for Biological Sciences, Ottawa, ON, and founder and Director General of the Institute for Biodiagnostics, Winnipeg, MB. He is a passionate advocate for the advancement of diagnostics for the early detection and treatment of disease.
He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada’s public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.
BRUCE COLWILL, DIRECTOR
Bruce Colwill is a strategic finance professional with over 25 years of experience in start-up and entrepreneurial companies. As the CFO of multiple public and private companies, Bruce has been responsible for fundraising in excess of US$400 million including private and public financing, debt and other structured financings.
GORDON MCCAULEY, DIRECTOR
President and CEO of Viable Healthworks Corp. and Chairman of Life Sciences BC. Co-founder and former President and COO of Neuro Discovery Inc. (NDI Capital). Past President and CEO of Allon Therapeutics.
KEITH B. CASSIDY, CFO
Keith Cassidy is an accountant with significant experience in professional services management (legal), as well as health care and education, at strategic and leadership levels. Keith Cassidy has served as VP Finance and CFO for the Royal Victoria Hospital.
He has held Executive Director positions with several major law firms including Davies Ward Phillips & Vineberg LLP; McMillan LLP; and Bennett Jones LLP. He has also lectured in Business Administration at John Abbott College in Montreal.
OMAR SAMASSEKOU, MD, PHD, VP, CLINICAL PROGRAMS
Oumar Samassekou, PhD, is trained in medical genetics, cytogenetics and other molecular genetics. During his Ph.D. and post-doctoral trainings, Dr. Samassekou developed expertise on prenatal diagnosis and cancer genomics. He has worked on the development of a non-invasive diagnostic procedure to detect fetal chromosomal abnormalities from maternal peripheral blood.
In regards to his background in cancer genomics research, Dr. Samassekou has studied the length of individual telomeres, telemetric nuclear architecture, and genomic instability in leukemia and breast cancer. In addition to his competencies in research, he has been trained in a clinical laboratory examining both molecular genetics and cytogenetics. Dr. Samassekou was the supervisor of a molecular pathology unit in one of the largest laboratories specializing in clinical pathology of breast cancer in Canada. Dr. Samassekou has also developed competency to supervise analytical and clinical validation of different clinical diagnostic, prognostic and predictive tests.
HUGH ROGERS, LLB, VP FINANCE
Mr. Rogers is an entrepreneur and lawyer with broad private and public company experience in business management, regulatory compliance, finance and investor relations. Recent work includes corporate finance advisory positions in a range of industries from health sciences and agribusiness to mining and oil and gas. Recent experience also includes corporate restructuring under the Companies’ Creditors Arrangement Act and disposition of distressed assets. Mr. Rogers holds a B.Sc. and LLB. He is a member in good standing of the Law Society of British Columbia.
CLINICAL AND SCIENTIFIC ADVISORY BOARD
Laurence Klotz – MD, FRCS(C)
Dr. Klotz is internationally recognized for his contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance (or “Watchful Waiting”) as a standard aspect of patient care. Dr. Klotz obtained his medical degree and residency training from the University of Toronto with a special fellowship in uro-oncology and tumour biology at Memorial Sloan Kettering Cancer Centre, New York. He is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations. He is a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Dr. Klotz was awarded the Order of Canada in 2016 for his contribution to prostate cancer treatment.
Hans Knecht – MD, FRCPC, FMH, FAMH
Dr. Knecht established himself as a prominent haematologist through his ground-breaking translational research on lymphoma biology. His current focus is on the molecular events leading to the transition from the mononuclear Hodgkin to the multinuclear Reed-Sternberg cell and the impact of 3D nuclear telomere organization on this transformation. Dr. Knecht received his medical degree from the University of Zurich, Switzerland with post-graduate work under both Maxime Seligmann (Haematology) and Karl Lennert (Haematopathology) in Paris and Lausanne, respectively. Dr. Knecht is currently a Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal.
Darrel Drachenberg – BSc, MD, FRCS(C)
Dr. Drachenberg is a urologic oncologist and researcher and strong proponent of Active Surveillance for prostate cancer patients. Dr. Drachenberg attended medical school at the University of British Columbia and urology residency at Dalhousie University. He is an American Foundation of Urology Scholar with fellowship training in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He founded the laparoscopic urology program and prostate brachytherapy, cryotherapy, and HIFU programs at the University of Manitoba where he works as assistant professor of surgery and director of research for the Manitoba Prostate Center and Section of Urology and Chair of the Genito-Urinary disease site group, CancerCare Manitoba.
Dr. Thomas Cremer – Professor emeritus of Anthropology and Human Genetics, Ludwig Maximilians University, Munich, Germany, Independent Expert
Dr. Cremer is an internationally-recognized scientist specializing in the studies of nuclear architecture. He is one of the pioneers of interphase cytogenetics and comparative genomic hybridization (CGH). These methods have become widely used tools for cytogenetic analyses of chromosomal imbalances.
He is a corresponding member of the Heidelberg Academy for Sciences and Humanities since 2000, a member of the Leopoldina since 2006, a honorary member of both the European Cytogenetics Association (ECA) and the German Society of Human Genetics since 2011, as well as the recipient of the medal of Honor of this Society.
Kenneth C. Anderson, MD
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics Institute Physician, Kraft Family Professor of Medicine, Harvard Medical School
Dr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at Dana-Farber Cancer Institute.
He serves as chief of the Division of Hematologic Neoplasia, director of the Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber.
BUSINESS ADVISORS
Jonathan Goodman, Director & CEO, Knight Therapeutics Inc.
Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later. Prior to co-founding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.
Dr. Heiner Dreismann, Past President and CEO, Roche Molecular Diagnostics
Dr. Dreismann is a seasoned executive with more than 24 years experience in the healthcare industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.
John Lindsay, Founder, SciPartners
Mr. Lindsay began his career at Millipore Corporation, Merck KGaA, and quickly advanced to become the youngest Vice President in the history of the company. He was promoted to Executive Vice President of several divisions, including the Analytical Group and Milligen Biosearch Divisions. In 2000, he founded SciPartners, with the objective of building a platform for development of early stage European and North American firms. His focus is the Life Science market, and over the past 14 years he has successfully built up sales and marketing that led to rapid growth and increased revenues for many companies, and the acquisition of ProXeon by ThermoFisher and the acquisition of Halo Genomics by Agilent.
Volume usually precedes a share price appreciation.
Well over 800,000 shares traded so far today the
most trading volume this month.
I sense HTBX could pop any time now.
I'm sure today's news is creating quite the buzz at the Bio Med Convention that is winding down in San Francisco today!
http://convention.bio.org/home.aspx
Vale to Cut Iron Ore Production..
http://www.australianmining.com.au/News/Vale-to-cut-iron-ore-production#%2EVl7Y_p-oexc%2Elinkedin
I listened in on today's conference call.
The team was well spoken and presented a well
laid out plan.
I'm looking forward to it's execution.
Global Hemp Group appoints Calkin, Gauthier as advisers
Global Hemp Group Inc (C:GHG)
Shares Issued 133,249,440
Last Close 3/2/2015 $0.035
Wednesday March 04 2015 - News Release
Mr. Charles Larsen reports
GLOBAL HEMP GROUP ANNOUNCES ROBERT CALKIN AND GABRIEL GAUTHIER AS STRATEGIC ADVISORS
Robert Calkin and Gabriel Gauthier, two veterans of the cannabis and hemp industries, have agreed to join Global Hemp Group Inc.'s international advisory board as strategic advisers.
Robert Calkin's experience in the cannabis industry is deep and broad. He founded CannaWorx, Inc., which owns and operates the Cannabis Career Institute, founded in 2009 and Cannabis State University, founded in 2010. He has also written the curriculum for Oakland's Oaksterdam University, which was the basis for his 2008 cannabis entrepreneurship bible "Starting Your Own Medical Marijuana Delivery Service: The Mobile Caregiver's Handbook." He is currently the instructor of Delivery 102 at Oaksterdam University. In 2011, Mr. Calkin created the industry's leading job listing and business development resource, Cannajobs.com, the most comprehensive online source for news and information relating to the medical cannabis industry. Mr. Calkin's experience, knowledge and extensive network in the cannabis industry will be invaluable to the Company as it embarks on cannabis related projects going forward.
Gabriel Gauthier is a pioneer in Canada in hemp construction. He brings to GHG a depth of experience and expertise in both hemp construction and hemp farming. Initially trained in landscape design, he then went to France for three years to train with Hemp Master Builders. After a two-year stint with Quebec's farm credit system, in 2003 he started his own hemp building company, ArtCan Enterprises. To date, they have undertaken more than 100 building and renovation projects using hemp technologies. In 2012, he expanded his interest to hemp cultivation and provided consulting services to prospective hemp farmers. He joined Groupe Orvert Ltd, a Quebec based company promoting hemp cultivation and processing, who's present activities focus on importing selected hemp seed to develop hemp production, then transforming the hemp to high value products. In this partnership, he farms about 250 ha in Quebec in association with a number of other farmers. Mr. Gauthier's experience and knowledge in hemp cultivation, processing and construction will be an important addition to the Company.
About ArtCan Enterprises
ArtCan ("AE"), created in 2003, is one of the oldest hemp construction enterprises in North America designing and constructing buildings that are both more durable and more comfortable. Such buildings are also carbon neutral and more economical to operate. With the experience of building or renovating over 100 projects in Quebec and Ontario, AE offers training sessions on hemp construction and assists prospective home-owners who wish to build their own houses. AE is very active in R&D and has developed its own hemp hurd lime mixture called Canalliance used in building walls, floor slabs and renderings, and has improved hemp processing machinery for construction. AE has also ventured into hemp farming in partnership with a number of farmers to source the raw materials needed for its construction activities, as there is currently a lack of readily available raw material available in Central Canada. www.hempconstruction.com
About CannaWorx, Inc.
CannaWorx is a multi-faceted company with a vast national network of cannabis scientists, medical specialists, and new product developers, cannabis industry experts, labor management and much more. CannaWorx offers a complete solution providing consistent access to hybridized cannabis strains, customized specific cannabinoid products to the cannabis business industry while maintaining highly experienced, trained industry experts, detailed cannabis data management, labor force management and proprietary formulations from high performance labs and grow facilities. The CannaWorx group of companies includes Cannabis Career Institute, Cannabis State University, CannaJobs, CannaTrends, Green Dot Delivery and more.
We seek Safe Harbor.
Well said Freewolf!
After reading yesterday's update, I am convinced this is a
win win situation.
Yes, there is nothing wrong with selling up to
250,000 cubic meters of overburden over the coming 9 months
to cover expenses. This process will expose more of the
ore body in advance before any commencement of production.
TNGL would reap around $90 a ton having upgraded their Fe ore
to a high grade 68% when the production decision is made.
Junior markets are tough right now and the management approach
makes perfect sense.
TONOGOLD RES INC (U-TNGL) - News Release
Tonogold - Strategy Update
2015-01-08 12:43 PT - News Release
LA JOLLA, CA / ACCESSWIRE / January 8, 2015 / Tonogold Resources Inc. (OTC: TNGL) wishes to advise the market with regard to its strategy in light of the current low iron ore price environment.
Background
Since completing the acquisition of Mil-Ler, the owner of the NevMex Iron Ore project in Mexico, Tonogold has been developing and formulating various strategies in light of the current weak environment for iron ore. The NevMex project has remained on care-and-maintenance during this period, at minimal holding cost and in doing so we are not suffering from operating losses being incurred by other producers as a result of the low iron ore price.
The NevMex iron ore project is located 40kms north of Hermosillo (the capital of Sonora, Northern Mexico). The ore is predominantly magnetite and utilizes a simple two-stage crushing and dry magnetic separation process that produced approx. 30,000 tonnes of iron ore per month containing 58% Fe. Total costs (including shipping to China) are about $55/t.
The current price for 58% Fe is approximately $63/t[1] to which an off-take discount of 18% ($11/t) was applied, mainly due to high sulfur levels (about 0.7%) in the final product.
Tonogold's strategy has been reviewed and it has been decided that delaying re-commencement of production, until we see signs of a price correction and/or confirmation of our ability to produce a higher quality product with increased margins, would be in the best interests of the Company.
We strongly believe that the current low iron ore price is not sustainable in the long run and that at a long-term sustainable price the NevMex project would generate positive net margins of at least $10/t, which exclude the benefit of any project optimization initiatives that we believe, can be achieved.
Optimization strategies
We are currently assessing a number of project optimization strategies including those that could provide significant benefits from milling and wet magnetic separation. In this regard, we have recently conducted, through an independent laboratory in Hermosillo, initial test-work on the 58% Fe product previously produced from the NevMex project. This test-work highlighted that by grinding the product to around 150 microns followed by wet magnetic separation, about 96% of the iron could be successfully recovered within 82% of the mass, resulting in a high-grade product containing +68% Fe being achieved. The current price for a 68% Fe product is around $90/t1 (i.e. $30/t higher than for a 58% Fe product).
Additional test-work is now planned to include further grind size/recovery optimization work as well as sulfur reduction with the objective of eliminating the sulfur penalty previously imposed. In addition, we have identified and are assessing various commercial opportunities (both organically and externally) that would enable us to produce a high-grade premium product in the medium-term.
Site Activities
Site activities have recently re-commenced whereby we are mining approximately 250,000 cubic meters of overburden (waste), over an expected 9-month period, crushing the material and selling the product as road base under contract with a local road contractor. The net proceeds from the sale of the road base will more than cover all site costs over this period, resulting in a zero-cost waste removal program and, at the same time, expose more of the ore body in advance of a subsequent production decision.
Gold
Our strategy with regard to our gold properties in Nevada has not changed and we continue to assess and pursue various opportunities (including sale, joint venture etc.) in order to realize the value of these assets in the near-term.
Capital Raising
In light of the new strategy and the current market conditions, we no longer need to raise $10 million previously contemplated which has therefore been deferred. However a smaller raising (of between $1.0 to 1.5 million) to Accredited Investors to fund the work program pursuant to the new strategy is now planned.
Iron Ore price
Current iron ore price ($71/t for 62% Fe CFR Qingdao basis) is trading below long-term levels necessary to provide economic supply/demand equilibrium. Various short/medium term issues have exacerbated the situation, including:
- Higher global production triggered by the rapid consumption and price increases in China during two periods; 2004-2008 and again in 2010-2012. China has accounted for 95% of the global demand increase since the year 2000.[2]
- As a result of the perceived continued growth of Chinese steel consumption, considerable over-investment has been focused on the sector. More than 60% of Chinese domestic iron production (more than 300 million tonnes) and nearly half of global supply, (more than 800 million tonnes) is currently unprofitable.[3]
- Large debt burdens, required to finance the infrastructure associated with many of the world's largest operations require those operations to sustain production even in a loss making price environment; advantaged producers are those with low Capital Expenditure per tonne of annual capacity which are not burdened by debt[3], such as Tonogold.
- Cumulative cost curve for iron ore confirms that the current price cannot be sustained in the long run, with few producers, outside the four largest, remaining profitable in today's environment.
CEO Comments
Tonogold's CEO, Mark Ashley, stated: "Although the current weakness in the global iron ore price is having a significant negative impact on the profitability of iron ore producers and, as result, their share prices, we have positioned ourselves such that we are effectively protected from the current price weakness."
He added, "Our revised strategy ensures that the inherent value of our iron ore assets are maintained, to be realized once we confirm the commercial viability of producing a high-grade premium product with significantly higher margins and/or the inevitable recovery in the iron ore price."
Tonogold Resources, Inc. is a minerals exploration company based in La Jolla, California. For more information on the company visit their website www.tonogold.com.
Safe Harbor Statement
This press release contains certain forward-looking information about Tonogold Resources, Inc. ("Tonogold") which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)", and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tonogold Resources, Inc. that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy, some of our managers lack formal training in the mining business, the grade and quantity of minerals in our projects may not be economic, we do not have fee title to our properties, but derive our rights through leases and the Mining Law, changes to the Mining Law may increase the cost of doing business, we are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission, we trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities, mining is subject to extensive environmental regulations and can create substantial environmental liabilities, gold, silver and other metals are commodities which have substantial price fluctuations, a drop in prices could adversely affect future profitability and capital raising efforts, and mining can be dangerous and present operational hazards for employees and contractors. Readers are cautioned not to place undue reliance on these forward-looking statements. Tonogold does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For further information please contact:
Mark Ashley
mjashley3@gmail.com
Phone: (858) 456-1273
[1] Based on 62% Fe Fines, CFR Qingdao Port of $71/t at January 8th, 2015
[2] Wood Mackenzie: Iron Ore: Readjusting Capital Investment to the New Reality, Nov 2014
[3] CRU Metals: Africa, a growing heavyweight in iron ore supply, June 2014
SOURCE: Tonogold Resources Inc.
Positive for Tonogold
Follow Hard Assets
Iron-Ore Miners cut 140 million tons of capacity
BY TIM LOH, BLOOMBERG
December 23, 2014 • Reprints
Iron-ore producers have canceled or suspended 22 mining projects since July as prices plunged to a five-year low, which will help to curb or even eliminate a supply surplus, according to Bloomberg Intelligence.
The cumulative cuts mean 140 million metric tons of extra capacity won’t now hit the global market over the next few years, according to Kenneth Hoffman, an analyst at Bloomberg Intelligence in Skillman, New Jersey.
Using an “aggressive” long-term assumption that demand for global shipments could grow 5 percent a year, the global iron-ore market would be in deficit by 2018, Hoffman said today in a report.
The price of the steelmaking ingredient delivered in Qingdao, China, was $66.84 a dry metric ton today, according to Metal Bulletin data, the lowest since June 2009. The price is down 50 percent this year.
More than 100 million tons of new capacity has entered the market since July, and that’s made the financing of new projects so challenging that even lower-cost mines are now being delayed or scrapped, Hoffman said.
Rio Tinto Group, the second-largest producer, said in November that it was deferring a final decision on its proposed Silvergrass mine in Australia. Also last month, Cliffs Natural Resources Inc. said it won’t pursue an expansion of its Bloom Lake mine in Canada and may close the operation.
Brazil, Australia
About 95 percent of new supply over the next five years is slated to come from Brazil and Australia, where the infrastructure is already in place, production costs are low and the ore quality is among the best, Hoffman said.
Despite the bear market for the commodity, more than 80 percent of global output is still profitable, due in part to China easing taxes and tariffs on miners and energy prices falling, he said.
Bloomberg Intelligence also outlined a bearish base case in which demand contracts 2 percent annually as China transitions from an economy driven by construction to one powered by services and manufacturing. In that case, Chinese steel demand may have already peaked in 2013 and “the world would be awash in iron ore for the foreseeable future,” Hoffman said.
Copyright 2014 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
This company has proven a disappointment
in terms of an investment.
Ashley's overall performance and optimizing market awareness
timed to TNGL news updates has been disappointing to say
the least.